<?xml version='1.0' encoding='UTF-8'?>
<!-- Created by Xince -->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:pharmabioserv.com="http://pharmabioserv.com/20230731" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023">
  <link:schemaRef xlink:href="./pbsv_taxonomy.zip/pbsv_taxonomy/pbsv-20230731.xsd" xlink:type="simple"/>
  <xbrli:context id="c">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c4">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c5">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c6">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c7">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c8">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c9">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c10">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c11">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c12">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c13">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-02-01</xbrli:startDate>
      <xbrli:endDate>2018-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c14">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c15">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c16">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-02-01</xbrli:startDate>
      <xbrli:endDate>2018-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c17">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c18">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c19">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c21">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c22">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c23">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c24">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c25">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c26">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c27">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c28">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c29">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c32">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c33">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerTotalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c34">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c35">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c36">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerTotalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c37">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c38">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c39">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c40">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c41">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c42">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c43">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c44">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c45">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:EuropeConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c46">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:EuropeConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c47">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c48">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:OtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c49">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c50">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c51">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:OtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c52">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-02-01</xbrli:startDate>
      <xbrli:endDate>2018-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c53">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c54">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c55">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:PuertoRicoConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c56">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c57">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c58">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:PuertoRicoConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c59">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c60">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:UnitedStatesConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c61">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c62">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c63">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:UnitedStatesConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c64">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c65">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:EuropeConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c66">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c67">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:EuropeConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c68">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c69">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:OtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c70">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c71">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c72">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:OtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c73">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c74">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c75">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c76">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c77">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c78">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c79">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c80">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-02-01</xbrli:startDate>
      <xbrli:endDate>2018-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c81">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c82">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c83">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c84">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c85">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerTotalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c86">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerTotalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c87">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-09-12</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c88">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerFMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c89">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c90">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerFMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c91">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerFMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c92">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerFMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c93">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c94">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c95">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c96">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c97">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c98">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c99">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c100">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c102">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c103">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c104">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c105">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c106">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupFMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c107">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c108">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:UnitedStatesConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c109">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c110">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:PuertoRicoConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c111">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupTotalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c112">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:PuertoRicoConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c113">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c114">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c115">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c116">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:UnitedStatesConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c117">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c118">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c119">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c120">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c121">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c122">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c123">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c124">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c125">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c126">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c127">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c128">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupFMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c129">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupTotalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c132">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c133">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c134">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c135">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c136">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c137">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c138">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c139">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c140">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupFMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c141">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c142">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupTotalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c143">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c144">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c145">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c146">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c147">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c148">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c149">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c150">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c151">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c152">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c153">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupFMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c154">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c155">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupTotalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c156">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c157">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2018-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c158">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c159">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c160">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="usd1">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <us-gaap:PrepaidExpenseAndOtherAssets id="f" decimals="0" contextRef="c" unitRef="usd">478577.0</us-gaap:PrepaidExpenseAndOtherAssets>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock id="f1" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;ORGANIZATION&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Pharma-Bio Serv, Inc. (&amp;#8220;Pharma-Bio&amp;#8221;)&#13;is a Delaware corporation organized on January 14, 2004. Pharma-Bio is the parent company of Pharma-Bio Serv PR, Inc. (&amp;#8220;Pharma-PR&amp;#8221;),&#13;Pharma Serv, Inc. (&amp;#8220;Pharma-Serv&amp;#8221;), and Scienza Labs, Inc. (&amp;#8220;Scienza Labs&amp;#8221;), each a&amp;#160;Puerto Rico corporation,&#13;Pharma-Bio Serv US, Inc. (&amp;#8220;Pharma-US&amp;#8221;), a Delaware corporation, Pharma-Bio Serv Validation &amp;#38; Compliance Limited&#13;(&amp;#8220;Pharma-IR&amp;#8221;), an Irish corporation currently inactive, Pharma-Bio Serv SL (&amp;#8220;Pharma-Spain&amp;#8221;), a Spanish&#13;limited liability company, and Pharma-Bio Serv Brasil Servicos de Consultoria Ltda. (&amp;#8220;Pharma-Brazil&amp;#8221;), a Brazilian&#13;limited liability company. Pharma-Bio, Pharma-PR, Pharma-Serv, Scienza Labs, Pharma-US, Pharma-IR, Pharma-Spain and Pharma-Brazil&#13;are collectively referred to as the &amp;#8220;Company.&amp;#8221; The Company operates in Puerto Rico, the United States, Europe and Brazil&#13;under the name of Pharma-Bio Serv and is engaged in providing technical compliance consulting service, and until September 17,&#13;2018 microbiological and chemical laboratory testing (the &amp;#8220;Lab&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;On September 17, 2018 (the &amp;#8220;Sales&#13;Closing Date&amp;#8221;), the Company sold substantially all of its Lab business assets (the &amp;#8220;Laboratory Assets&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;SUMMARY OF SIGNIFICANT ACCOUNTING&#13;POLICIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The condensed consolidated balance&#13;sheet of the Company as of October 31, 2018 is derived from audited consolidated financial statements but does not include all&#13;disclosures required by generally accepted accounting principles. The unaudited interim condensed consolidated financial statements,&#13;include all adjustments, consisting of normal recurring adjustments, which are, in the opinion of management, necessary for a fair&#13;presentation of the financial position and results of operations and cash flows for the interim periods. The results of operations&#13;for the nine months ended July 31, 2019 are not necessarily indicative of expected results for the full 2019 fiscal year.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The accompanying financial data&#13;as of July 31, 2019, and for the three-month and nine-month periods ended July 31, 2019 and 2018 has been prepared by us, without&#13;audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;). Certain information&#13;and footnote disclosures normally contained in financial statements prepared in accordance with generally accepted accounting principles&#13;have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the financial&#13;statements and notes contained in our audited Consolidated Financial Statements and the notes thereto for the fiscal year ended&#13;October 31, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;Consolidation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The accompanying condensed consolidated&#13;financial statements include the accounts of the Company and all of its wholly owned subsidiaries. All intercompany transactions&#13;and balances have been eliminated in consolidation.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;Segments&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;On the Sales Closing Date, the&#13;Company sold substantially all of its Laboratory Assets. As a result of the sale, the Company currently operates in three reportable&#13;business segments: (i) Puerto Rico technical compliance consulting, (ii) United States technical compliance consulting, and (iii)&#13;Europe technical compliance consulting. Accordingly, the accompanying consolidated financial statements are presented to show these&#13;three reportable segments as continuing operations, while the Lab is presented as a discontinued operation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The preparation of condensed&#13;consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires&#13;management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent&#13;assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and&#13;expenses during the reporting periods. Actual results may differ from these estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Accounting standards have established&#13;a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs&#13;when measuring fair value. A financial instrument&amp;#8217;s categorization within the fair value hierarchy is based upon the lowest&#13;level of input that is significant to the fair value measurement. Accounting standards have established three levels of inputs&#13;that may be used to measure fair value:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 12%; padding-right: 13.5pt; padding-left: 0.25in; font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt"&gt;&lt;i&gt;Level&amp;#160;1&lt;/i&gt;:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 6%; padding-right: 13.5pt; padding-left: 0.25in; font: 12pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 82%"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0.25in; text-align: justify"&gt;Quoted prices in active markets&#13;        for identical assets and liabilities.&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; padding-right: 13.5pt; padding-left: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;i&gt;Level&amp;#160;2:&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-right: 13.5pt; padding-left: 0.25in"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0.25in; text-align: justify"&gt;Observable inputs other than&#13;        Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets with insufficient volume or infrequent&#13;        transactions (less active markets), or model-derived valuations in which all significant inputs are observable or can be derived&#13;        principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; padding-right: 13.5pt; padding-left: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;i&gt;Level&amp;#160;3&lt;/i&gt;:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-right: 13.5pt; padding-left: 0.25in"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-right: 13.5pt; padding-left: 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The carrying value of the Company's&#13;financial instruments (excluding obligations under capital leases), cash and cash equivalents, accounts receivable, accounts payable&#13;and accrued liabilities, are considered reasonable estimates of fair value due to their liquidity or short-term nature. Management&#13;believes, based on current rates, that the fair value of its obligations under capital leases approximates the carrying amount.&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 6.6pt 0pt; text-align: justify"&gt;In May 2014, the Financial&#13;Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for the recognition of revenue from&#13;contracts with customers to transfer goods and services. The FASB subsequently issued additional, clarifying standards to address&#13;issues arising from implementation of the new revenue recognition standard. The new revenue recognition standard and clarifying&#13;standards require an entity to recognize revenue when control of promised goods or services is transferred to the customer at an&#13;amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We adopted&#13;this new standard as of November 1, 2018, by applying the modified-retrospective method to those contracts that were not completed&#13;as of that date. The results for reporting periods beginning after November 1, 2018, are presented in accordance with the new standard,&#13;although comparative information has not been restated and continues to be reported under the accounting standards and policies&#13;in effect for those periods. The adoption of this new standard had an immaterial impact on our reported total revenues and operating&#13;income as compared to what reported amounts would have been under the prior standard.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Revenue is primarily derived&#13;from: (1) time and materials contracts (representing approximately 99% of total revenues), which is recognized by applying the&#13;proportional performance model, whereby revenue is recognized as performance occurs, and (2) short-term fixed-fee contracts or&#13;&amp;#34;not to exceed&amp;#34; contracts (representing approximately 1% of total revenues), which revenue is recognized similarly, except&#13;that certain milestones also have to be reached before revenue is recognized. If the Company determines that a contract will result&#13;in a loss, the Company recognizes the estimated loss in the period in which such determination is made.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;Cash Equivalents&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;For purposes of the consolidated&#13;statements of cash flows, cash equivalents include investments in a money market obligations trust that is registered under the&#13;U.S. Investment Company Act of 1940, as amended, and liquid investments with original maturities of three months or less.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;Accounts Receivable&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Accounts receivable are recorded&#13;at their estimated realizable value. Accounts are deemed past due when payment has not been received within the stated time period.&#13;The Company's policy is to review individual past due amounts periodically and write off amounts for which all collection efforts&#13;are deemed to have been exhausted. Due to the nature of the Company&amp;#8217;s customers, bad debts are mainly accounted for using&#13;the direct write-off method whereby an expense is recognized only when a specific account is determined to be uncollectible. The&#13;effect of using this method approximates that of the allowance method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The Company follows an asset&#13;and liability approach method of accounting for income taxes. This method measures deferred income taxes by applying enacted statutory&#13;rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported&#13;amounts on the financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws&#13;as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The Company follows guidance&#13;from the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) related to &lt;i&gt;Accounting for Uncertainty in Income Taxes,&lt;/i&gt;&#13;which includes a two-step approach to recognizing, de-recognizing and measuring uncertain tax positions. As of July 31, 2019, the&#13;Company had no significant uncertain tax positions that would be reduced as a result of a lapse of the applicable statute of limitations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Owned property and equipment,&#13;and leasehold improvements are stated at cost. Vehicles under capital leases are stated at the lower of fair market value or net&#13;present value of the minimum lease payments at the inception of the leases.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Depreciation and amortization&#13;of owned assets are provided for, when placed in service, in amounts sufficient to relate the cost of depreciable assets to operations&#13;over their estimated service lives, using straight-line basis. Assets under capital leases and leasehold improvements are amortized&#13;over the shorter of the estimated useful lives of the assets or the lease term, including renewals that have been determined to&#13;be reasonable assured. Major renewals and betterments that extend the life of the assets are capitalized, while expenditures for&#13;repairs and maintenance are expensed when incurred. As of July 31, 2019 and October 31, 2018, the accumulated depreciation and&#13;amortization amounted to $483,983 and $496,953, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The Company evaluates for impairment&#13;its long-lived assets to be held and used, and long-lived assets to be disposed of, whenever events or changes in circumstances&#13;indicate that the carrying amount of an asset may not be recoverable. Based on management estimates, no impairment of the operating&#13;properties was present as of July 31, 2019 and October 31, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;Stock-based Compensation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Stock-based compensation expense&#13;is recognized in the consolidated financial statements based on the fair value of the awards granted. Stock-based compensation&#13;cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service&#13;period, which generally represents the vesting period, and includes an estimate of awards that will be forfeited. The Company calculates&#13;the fair value of stock options using the Black-Scholes option-pricing model at the grant date, while for restricted stock units&#13;the fair market value of the units is determined by Company&amp;#8217;s share market value at grant date. Excess tax benefits related&#13;to stock-based compensation are reflected as cash flows from financing activities rather than cash flows from operating activities.&#13;The Company has not recognized such cash flows from financing activities since there has been no tax benefit related to the stock-based&#13;compensation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;Earnings (Loss) Per Share&#13;of Common Stock&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Basic earnings (loss) per share&#13;of common stock is calculated by dividing net earnings (loss) by the weighted average number of shares of common stock outstanding.&#13;Diluted earnings (loss) per share includes the dilution of common stock equivalents, which include principally shares that may&#13;be issued upon the exercise of warrants, stock option and restricted stock unit awards.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The diluted weighted average&#13;shares of common stock outstanding were calculated using the treasury stock method for the respective periods.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;Foreign Operations&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The functional currency of the&#13;Company&amp;#8217;s foreign subsidiaries is its local currency. The assets and liabilities of the Company&amp;#8217;s foreign subsidiaries&#13;are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated&#13;at the average exchange rates prevailing during the period. The cumulative translation effect for subsidiaries using a functional&#13;currency other than the U.S. dollar is included as a cumulative translation adjustment in stockholders&amp;#8217; equity and as a component&#13;of comprehensive income.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The Company&amp;#8217;s intercompany&#13;accounts are typically denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement&#13;of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation&#13;adjustment in stockholders&amp;#8217; equity and as a component of comprehensive income, while gains and losses resulting from the&#13;remeasurement of intercompany receivables from those international subsidiaries for which the Company anticipates settlement in&#13;the foreseeable future are recorded in the consolidated statements of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt"&gt;&lt;b&gt;Subsequent Events&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The Company has evaluated subsequent&#13;events through&amp;#160;the filing date of this report. The Company has determined that there are no events occurring in this period&#13;that required disclosure or adjustment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;Reclassifications&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Certain reclassifications have&#13;been made to the July 31, 2018 condensed consolidated financial statements to conform them to the July 31, 2019 condensed consolidated&#13;financial statements presentation. Such reclassifications do not affect net income (loss) as previously reported.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt"&gt;&lt;b&gt;Recent accounting pronouncements not implemented&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;In February 2016, the FASB issued&#13;a new accounting standard that amends the guidance for the accounting and disclosure of leases. This new standard requires that&#13;lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative&#13;information about their leasing arrangements. The new standard is effective for interim and annual periods beginning on January&#13;1, 2019 and may be adopted earlier. This standard is effective for the Company&amp;#8217;s first quarter of fiscal year 2020. The Company&#13;does not expect that this standard will have a material impact to its Consolidated Statements of Operations but expects that this&#13;standard will have a material impact on the assets and liabilities on its Consolidated Balance Sheets upon adoption.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="f2" decimals="0" contextRef="c2" unitRef="usd">3526991.0</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:PropertyPlantAndEquipmentNet id="f3" decimals="0" contextRef="c" unitRef="usd">306817.0</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:GainLossOnDispositionOfAssets id="f4" decimals="0" contextRef="c3" unitRef="usd">0.0</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:Assets id="f5" decimals="0" contextRef="c" unitRef="usd">26251082.0</us-gaap:Assets>
  <us-gaap:NetCashProvidedByUsedInDiscontinuedOperations id="f6" decimals="0" contextRef="c2" unitRef="usd">403567.0</us-gaap:NetCashProvidedByUsedInDiscontinuedOperations>
  <us-gaap:GainLossOnDispositionOfAssets id="f7" decimals="0" contextRef="c2" unitRef="usd">0.0</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:AssetsCurrent id="f8" decimals="0" contextRef="c4" unitRef="usd">23411797.0</us-gaap:AssetsCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="f9" decimals="0" contextRef="c" unitRef="usd">7802447.0</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:OtherAssetsNoncurrent id="f10" decimals="0" contextRef="c" unitRef="usd">367547.0</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:GainLossOnDispositionOfAssets id="f11" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:Assets id="f12" decimals="0" contextRef="c4" unitRef="usd">25378312.0</us-gaap:Assets>
  <us-gaap:OtherLiabilities id="f13" decimals="0" contextRef="c" unitRef="usd">17950.0</us-gaap:OtherLiabilities>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="f14" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;For purposes of the consolidated&#13;statements of cash flows, cash equivalents include investments in a money market obligations trust that is registered under the&#13;U.S. Investment Company Act of 1940, as amended, and liquid investments with original maturities of three months or less.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:OtherAssetsNoncurrent id="f15" decimals="0" contextRef="c4" unitRef="usd">418495.0</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:MarketableSecuritiesTextBlock id="f16" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 8pt 0pt; text-align: justify"&gt;On September 17, 2018, the&#13;Company completed the sale of its Laboratory Assets for $5 million and received, as partial payment, a $3 million Promissory Note&#13;from the purchaser. The Promissory Note is composed of two tranches; (i) Tranche A for $2 million and secured with lab equipment&#13;and (ii) Tranche B for $1 million which is unsecured. The interest rate accrual is 3% for Tranche A and 5% for Tranche B. Interest&#13;is due semi-annually in arrears commencing on the six-month after the Sales Closing Date. Tranche A is due in two installments&#13;of $750,000 and $1,250,000, on September 17, 2019 and 2020, respectively. Tranche B first installment of $500,000 was collected&#13;during the quarter ended April 30, 2019, and a second installment of $500,000 is due on September 17, 2019.&lt;/p&gt;</us-gaap:MarketableSecuritiesTextBlock>
  <us-gaap:PropertyPlantAndEquipmentNet id="f17" decimals="0" contextRef="c4" unitRef="usd">298020.0</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="f18" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;On December 2014, the Company&#13;entered into an agreement with a firm for providing (i) business development and (ii) mergers and acquisition services to the Company.&#13;Pursuant to the agreement terms, the Company issued warrants for the purchase of 1,000,000 common shares at an exercise price of&#13;$1.80 per share. The underlying common shares of the warrants are fully vested and expire on December 1, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="f19" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Accounting standards have established&#13;a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs&#13;when measuring fair value. A financial instrument&amp;#8217;s categorization within the fair value hierarchy is based upon the lowest&#13;level of input that is significant to the fair value measurement. Accounting standards have established three levels of inputs&#13;that may be used to measure fair value:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 12%; padding-right: 13.5pt; padding-left: 0.25in; font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt"&gt;&lt;i&gt;Level&amp;#160;1&lt;/i&gt;:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 6%; padding-right: 13.5pt; padding-left: 0.25in; font: 12pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 82%"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0.25in; text-align: justify"&gt;Quoted prices in active markets&#13;        for identical assets and liabilities.&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; padding-right: 13.5pt; padding-left: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;i&gt;Level&amp;#160;2:&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-right: 13.5pt; padding-left: 0.25in"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0.25in; text-align: justify"&gt;Observable inputs other than&#13;        Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets with insufficient volume or infrequent&#13;        transactions (less active markets), or model-derived valuations in which all significant inputs are observable or can be derived&#13;        principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; padding-right: 13.5pt; padding-left: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;i&gt;Level&amp;#160;3&lt;/i&gt;:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-right: 13.5pt; padding-left: 0.25in"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-right: 13.5pt; padding-left: 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The carrying value of the Company's&#13;financial instruments (excluding obligations under capital leases), cash and cash equivalents, accounts receivable, accounts payable&#13;and accrued liabilities, are considered reasonable estimates of fair value due to their liquidity or short-term nature. Management&#13;believes, based on current rates, that the fair value of its obligations under capital leases approximates the carrying amount.&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="f20" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;On the Sales Closing Date, the&#13;Company sold substantially all of its Laboratory Assets. As a result of the sale, the Company currently operates in three reportable&#13;business segments: (i) Puerto Rico technical compliance consulting, (ii) United States technical compliance consulting, and (iii)&#13;Europe technical compliance consulting. Accordingly, the accompanying consolidated financial statements are presented to show these&#13;three reportable segments as continuing operations, while the Lab is presented as a discontinued operation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="f21" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;On December 22, 2017, Public&#13;Law 115-97, commonly known as the Tax Cuts and Jobs Act of 2017 (the &amp;#8220;Tax Reform&amp;#8221;), was enacted. The Tax Reform is&#13;applicable to the Company commencing with its fiscal year 2018. The Tax Reform imposed a mandatory one-time transition tax (the&#13;&amp;#8220;Transition Tax&amp;#8221;) over foreign subsidiaries undistributed earnings and profits (&amp;#8220;E&amp;#38;Ps&amp;#8221;) earned prior&#13;to a date set by the statute. Based on the Company&amp;#8217;s E&amp;#38;Ps, the Transition Tax is estimated to be approximately $2.7 million.&#13;The Transition Tax liability may be paid over a period of eight years starting with the Company&amp;#8217;s fiscal year 2019. In the&#13;past, most of these E&amp;#38;Ps&amp;#8217; were not repatriated since such E&amp;#38;Ps&amp;#8217; were considered to be reinvested indefinitely&#13;in the foreign location, therefore no US tax liability was incurred unless the E&amp;#38;Ps were repatriated as a dividend. After December&#13;31, 2017, the Tax Reform has established a 100% tax exemption on the foreign-source portion of dividends received attributable&#13;to E&amp;#38;Ps, with certain limitations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;In June 2011, Pharma-Bio, Pharma-PR&#13;and Pharma-Serv obtained a Grant of Industrial Tax Exemption pursuant to the terms and conditions set forth in Act No. 73 of May&#13;28, 2008 (&amp;#8220;the Grant&amp;#8221;) issued by the Puerto Rico Industrial Development Company (&amp;#8220;PRIDCO&amp;#8221;). The Grant was&#13;effective as of November 1, 2009 and covers a fifteen-year period. The Grant provides relief on various Puerto Rico taxes, including&#13;income tax, with certain limitations, for most of the activities carried on within Puerto Rico, including those that are for services&#13;to parties located outside of Puerto Rico. Industrial Development Income (&amp;#8220;IDI&amp;#8221;) covered under the Grant are subject&#13;to a fixed income tax rate of 4%. In addition, IDI earnings distributions accumulated since November 1, 2009 are totally exempt&#13;from Puerto Rico earnings distribution tax.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Puerto Rico operations not covered&#13;in the exempt activities of the Grant are subject to Puerto Rico income tax at a maximum tax rate of 39% as provided by the 1994&#13;Puerto Rico Internal Revenue Code, as amended. The operations carried out in the United States by the Company&amp;#8217;s subsidiary&#13;was taxed in the United States at a maximum regular federal income tax rate of 35%. Among the Tax Reform provisions, effective&#13;with the Company&amp;#8217;s fiscal year ending on October 31, 2018, is a provision whereby the regular federal income tax rate is&#13;reduced to a 23.5% blended rate and 21% thereafter.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Deferred income tax assets and&#13;liabilities are computed for differences between the consolidated financial statements and tax bases of assets and liabilities&#13;that will result in taxable or deductible amounts in the future, based on enacted tax laws and rates applicable to the periods&#13;in which the differences are expected to affect taxable income.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Pharma-Spain, Pharma-IR, Pharma-Bio/Pharma-US,&#13;Pharma-PR and Pharma-Serv have unused operating losses which result in a potential deferred tax asset. However, an allowance has&#13;been provided covering the total amount of such balance since it is uncertain whether the net operating losses can be used to offset&#13;future taxable income before their expiration dates. Realization of future tax benefits related to a deferred tax asset is dependent&#13;on many factors, including the company&amp;#8217;s ability to generate taxable income. Accordingly, the income tax benefit will be&#13;recognized when realization is determined to be more probable than not. These net operating losses are available to offset future&#13;taxable income through 2033 for Pharma-Spain; indefinitely for Pharma-IR; until 2038 for Pharma-Bio/Pharma-US; until 2027 for Pharma-PR&#13;and Pharma-Serv.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The Company files income tax&#13;returns in the United States (federal and various states jurisdictions), Puerto Rico, Ireland, Spain and Brazil. The 2015 (2014&#13;for Puerto Rico) through 2018 tax years are open and may be subject to potential examination in one or more jurisdictions. Currently,&#13;the Company has no federal, state, Puerto Rico or foreign income tax examination.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:AccountsReceivableNetCurrent id="f22" decimals="0" contextRef="c4" unitRef="usd">5193385.0</us-gaap:AccountsReceivableNetCurrent>
  <pharmabioserv.com:PromissoryNoteReceivableCurrent id="f23" decimals="0" contextRef="c" unitRef="usd">1250000.0</pharmabioserv.com:PromissoryNoteReceivableCurrent>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="f24" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;On June 13, 2014, the Board&#13;of Directors of the Company authorized the Company to repurchase up to two million shares of its outstanding common stock (the&#13;&amp;#8220;Repurchase Program&amp;#8221;). The timing, manner, price and amount of any repurchases under the Repurchase Program will be&#13;at the discretion of the Company, subject to the requirements of the Securities Exchange Act of 1934, as amended, and related rules.&#13;The Repurchase Program does not oblige the Company to repurchase any shares and it may be modified, suspended or terminated at&#13;any time and for any reason. No shares will be repurchased under the Repurchase Program directly from directors or officers of&#13;the Company. As of July 31, 2019 and October 31, 2018, a total of 338,854 and 315,404 shares of the Company&amp;#8217;s common stock&#13;were purchased under the Repurchase Program for an aggregate amount of $329,607 and $304,688, respectively. Also, on November 26,&#13;2018, the Company repurchased 62,972 shares of common stock, outside of the Repurchase Program, from the Company&amp;#8217;s Chief&#13;Executive Officer at $1.00 per share. These shares were repurchased at a discount to market to provide for an orderly disposition&#13;of the shares.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:PrepaidExpenseAndOtherAssets id="f25" decimals="0" contextRef="c4" unitRef="usd">438492.0</us-gaap:PrepaidExpenseAndOtherAssets>
  <us-gaap:DepreciationDepletionAndAmortization id="f26" decimals="0" contextRef="c2" unitRef="usd">64737.0</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:EarningsPerShareTextBlock id="f27" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The following data shows the&#13;amounts used in the calculations of basic and diluted earnings (losses) per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 3pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: white 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Three months ended July 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Nine months ended July 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 3pt solid; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCFFCC"&gt;&#13;    &lt;td style="vertical-align: bottom; width: 50%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;font style="font-size: 8pt"&gt;Net income (loss) available to common equity holders - used to compute basic and diluted earnings (losses) per share (continuing operations)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; border-bottom: Black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; border-bottom: Black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;431,158&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; border-bottom: Black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; border-bottom: Black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;721,819&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; border-bottom: Black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 8%; border-bottom: Black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,609,661&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; border-bottom: Black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1,759,178&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt"&gt;&lt;font style="font-size: 8pt"&gt;Net income (loss) available to common equity holders - used to compute basic and diluted earnings (losses) per share (discontinued operations)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,812&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(302,551&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCFFCC"&gt;&#13;    &lt;td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white"&gt;&#13;    &lt;td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt"&gt;&lt;font style="font-size: 8pt"&gt;Weighted average number of common shares - used to compute basic earnings (losses) per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;22,996,169&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,062,531 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,045,432&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,076,306&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCFFCC"&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;Effect of warrants to purchase common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;Effect of restricted stock units to common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCFFCC"&gt;&#13;    &lt;td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt"&gt;&lt;font style="font-size: 8pt"&gt;Effect of options to purchase common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;42,067&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12,075&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;63,320&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,452&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt"&gt;&lt;font style="font-size: 8pt"&gt;Weighted average number of shares - used to compute diluted earnings (losses) per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,038,236&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,074,606&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,108,752&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,080,758&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;For the three-month and nine-month&#13;periods ended July 31, 2019 and 2018, warrants for the purchase of shares of 1,000,000 common stock were not considered in computing&#13;diluted earnings per share because the effect was antidilutive. In addition, options for the purchase of 240,000 and 80,000 shares&#13;of common stock for the three-month and nine-month periods ended July 31, 2019, respectively, and 620,000 shares of common stock&#13;for the three-month and nine-month periods ended July 31, 2018, were not included in computing diluted earnings (losses) per share&#13;because their effects were also antidilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock id="f28" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;During September 2017, the Company&amp;#8217;s&#13;Puerto Rico operations were affected by hurricanes which severely impacted Puerto Rico (&amp;#8220;Hurricanes&amp;#8221;). The Hurricanes&#13;related insurance claim for business interruption losses and additional expenses incurred by the Company until electrical power&#13;and other basic utilities were restored was settled with the insurance carrier on April 2019 for the aggregate amount of approximately&#13;$199,000. Last fiscal year, the insurance claim for property damages resulting from the Hurricanes was settled with the insurance&#13;carrier on July 2018 for the aggregate amount of approximately $148,000. Based on current accounting guidance, the insurance proceeds&#13;were recognized upon collection, as a gain contingency against other income in the accompanying condensed financial statements&#13;for the applicable period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Administered and disbursed by the Puerto&#13;Rico Treasury Department, the United States federal government granted a salaries subsidy (the &amp;#8220;Salaries Subsidy&amp;#8221;)&#13;to Puerto Rico employers which retained employees for the period since the Hurricanes until the sooner of (i) when the employer&#13;operations were fully able to operate or (ii) December 31, 2017. During July of last fiscal year, the Company&amp;#8217;s Puerto Rico&#13;subsidiaries applied and collected from the Salaries Subsidy an aggregate amount of approximately $220,000. During the three months&#13;ended July 31, 2018, this Salaries Subsidy was recorded against other income in the accompanying condensed financial statements.&lt;/p&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
  <us-gaap:SegmentReportingDisclosureTextBlock id="f29" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The Company&amp;#8217;s segments are based&#13;on the organizational structure for which financial results are regularly evaluated by the Company&amp;#8217;s chief operating decision&#13;maker to determine resource allocation and assess performance. Each reportable segment is managed by its own management team and&#13;reports to executive management. The Company has three reportable segments: (i) Puerto Rico technical compliance consulting, (ii)&#13;United States technical compliance consulting, and (iii) Europe technical compliance consulting. These reportable segments provide&#13;services primarily to the pharmaceutical, chemical, medical device and biotechnology industries in their respective markets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The following table presents information&#13;about the reported revenue from services and earnings from continuing operations of the Company for the three-month and nine-month&#13;periods ended in July 31, 2019 and 2018. There is no intersegment revenue for the mentioned periods. Corporate expenses that support&#13;the operating units have been allocated to the segments. Asset information by reportable segment is not presented, since the Company&#13;does not produce such information internally, nor does it use such data to manage its business.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 3pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: white 3pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Three months ended July 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Nine months ended July 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 3pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 3pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: white 3pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-top: white 1pt solid; border-bottom: white 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;REVENUES:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; text-indent: 9pt"&gt;&lt;font style="font-size: 8pt"&gt;Puerto Rico consulting&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,383,121&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,825,157&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12,564,716&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;9,737,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-indent: 9pt"&gt;&lt;font style="font-size: 8pt"&gt;United States consulting&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;502,998&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;684,051&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,690,999&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,311,882&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-indent: 9pt"&gt;&lt;font style="font-size: 8pt"&gt;Europe consulting&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;33,379&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;111,156&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;266,610&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,042,086&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; padding-left: 0.25in; text-indent: -9pt"&gt;&lt;font style="font-size: 8pt"&gt;Other segments&amp;#185;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;47,021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10,939&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;160,735&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;31,403&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; padding-left: 0.25in; text-indent: -0.1pt"&gt;&lt;font style="font-size: 8pt"&gt;Total consolidated revenues&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: white"&gt;&lt;font style="font-size: 8pt"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,966,519&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: white"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,631,303&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: white"&gt;&lt;font style="font-size: 8pt"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;14,683,060&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: white"&gt;&lt;font style="font-size: 8pt"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12,123,257&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;INCOME (LOSS) BEFORE TAXES:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-indent: 9pt"&gt;&lt;font style="font-size: 8pt"&gt;Puerto Rico consulting&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;359,648&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;535,526&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,315,937&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;520,786&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-indent: 9pt"&gt;&lt;font style="font-size: 8pt"&gt;United States consulting&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(38,037&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;42,737&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(35,717&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(132,964&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-indent: 9pt"&gt;&lt;font style="font-size: 8pt"&gt;Europe consulting&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(87,968&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(104,921&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(145,893&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;72,884&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; text-indent: 9pt"&gt;&lt;font style="font-size: 8pt"&gt;Other segments&amp;#185;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;208,897&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;301,443&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom"&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;604,929&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;534,105&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-indent: 17.9pt"&gt;&lt;font style="font-size: 8pt"&gt;Total consolidated income before taxes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;442,540&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;774,785&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,739,256&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;994,811&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 4%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#185;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 59%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Other segments represent activities that fall below the reportable threshold and are carried out&#13;in Puerto Rico and Brazil. These activities include a Brazilian compliance consulting division and corporate headquarters, as&#13;applicable.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 37%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Long lived assets (property&#13;and equipment) as of July 31, 2019 and October 31, 2018, and related depreciation and amortization expense for the three and nine&#13;months ended July 31, 2019 and 2018, were concentrated in the corporate headquarters in Puerto Rico. Accordingly, depreciation&#13;expense and acquisition of property and equipment, as presented in the statements of cash flows are mainly related to the corporate&#13;headquarters.&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <us-gaap:ConcentrationRiskDisclosureTextBlock id="f30" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The Company&amp;#8217;s domestic cash and&#13;cash equivalents consist of cash deposits in FDIC insured banks (substantially covered by FDIC insurance by the spread of deposits&#13;in multiple FDIC insured banks), a money market obligations trust registered under the US Investment Company Act of 1940, as amended,&#13;and U.S. Treasury securities with maturities of three months or less. In the foreign markets we serve, we also maintain cash deposits&#13;in foreign banks, which have no specific insurance. No losses have been experienced or are expected on these accounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&lt;b&gt;Accounts receivable and revenues&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Management deems all of its accounts&#13;receivable to be fully collectible, and, as such, does not maintain any allowances for uncollectible receivables.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The Company's revenues, and the related&#13;receivables, are concentrated in the pharmaceutical industry in Puerto Rico, the United States, Ireland, Spain and Brazil. Although&#13;a few customers represent a significant source of revenue, the Company&amp;#8217;s functions are not a continuous process, accordingly,&#13;the client base for which the services are typically rendered, on a project-by-project basis, changes regularly.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The Company provided a substantial portion&#13;of its services to six customers, which accounted for 10% or more of its revenues in either of the three-month and nine-month periods&#13;ended July 31, 2019 and 2018. During the three months ended July 31, 2019, revenues from these customers were 30.0%, 14.1%, 9.8%,&#13;9.6%, 2.2% and 3.5%, or a total of 69.2%, as compared to the same period last year of 6.9%, 1.8%, 9.8%, 7.5%, 22.6% and 10.1%,&#13;or a total of 58.7%, respectively. During the nine months ended July 31, 2019, revenues from these customers were 24.8%, 9.7%,&#13;11.0%, 10.2%, 6.6%, and 5.1%, or a total of 67.4%, as compared to the same period last year of 7.2%, 3.1%, 14.1%, 7.7%, 13.1% and&#13;9.2%, or a total of 54.4%, respectively. At July 31, 2019, amounts due from these customers represented 81.5% of the Company&amp;#8217;s&#13;total accounts receivable balance. This customer information is based on revenues earned from said customers at the segment level&#13;because in management&amp;#8217;s opinion contracts by segments are totally independent of each other, and therefore such information&#13;is more meaningful to the reader.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;At the global level, six global groups&#13;of affiliated companies accounted for 10% or more of its revenues in either of the three-month and nine-month periods ended July&#13;31, 2019 and 2018. During the three months ended July 31, 2019, aggregate revenues from these global groups of affiliated companies&#13;were 30.0%, 17.3%, 9.8%, 9.6%, 2.2%, and 3.5%, or a total of 72.4%, as compared to the same period last year for 6.9%, 4.2%, 9.8%,&#13;7.5%, 22.6%, and 10.1%, or a total of 61.1%, respectively. During the nine months ended July 31, 2019, aggregate revenues from&#13;these global group of affiliated companies were 24.8%, 12.9%, 11.0, 10.2%, 6.6% and 5.1%, or a total of 70.6%, as compared to the&#13;same period last year for 7.2%, 5.7%, 14.0%, 7.7%, 13.1% and 9.3%, or a total of 57.0%, respectively. At July 31, 2019, amounts&#13;due from these global groups of affiliated companies represented 82.8% of total accounts receivable balance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;As of July 31, 2019, one of the Company&amp;#8217;s&#13;customers owes the Company approximately $6.1 million (including $2.5 million from a Promissory Note), which represents approximately&#13;27.6% of the Company&amp;#8217;s total working capital. We are providing multiple services to this customer related to their construction&#13;of a manufacturing facility in Puerto Rico. From this facility the customer will do the manufacturing and distribution of an existing&#13;product and an investigational new drug to be marketed to worldwide markets, once approved by regulators. A significant portion&#13;of the customer&amp;#8217;s funding comes from different financing sourcing. Management estimates that collectability of the account&#13;is reasonably assured, accordingly, no provision for losses, if any, have been recorded in the financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
  <us-gaap:CommonStockSharesIssued id="f31" decimals="INF" contextRef="c" unitRef="shares">23397707.0</us-gaap:CommonStockSharesIssued>
  <pharmabioserv.com:PromissoryNoteReceivable id="f32" decimals="0" contextRef="c" unitRef="usd">1250000.0</pharmabioserv.com:PromissoryNoteReceivable>
  <pharmabioserv.com:PromissoryNoteReceivableCurrent id="f33" decimals="0" contextRef="c4" unitRef="usd">1750000.0</pharmabioserv.com:PromissoryNoteReceivableCurrent>
  <us-gaap:UseOfEstimates id="f34" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The preparation of condensed&#13;consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires&#13;management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent&#13;assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and&#13;expenses during the reporting periods. Actual results may differ from these estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:SubsequentEventsPolicyPolicyTextBlock id="f35" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The Company has evaluated subsequent&#13;events through&amp;#160;the filing date of this report. The Company has determined that there are no events occurring in this period&#13;that required disclosure or adjustment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
  <us-gaap:PreferredStockSharesOutstanding id="f36" decimals="INF" contextRef="c" unitRef="shares">0.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ConsolidationPolicyTextBlock id="f37" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The accompanying condensed consolidated&#13;financial statements include the accounts of the Company and all of its wholly owned subsidiaries. All intercompany transactions&#13;and balances have been eliminated in consolidation.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <pharmabioserv.com:PromissoryNoteReceivable id="f38" decimals="0" contextRef="c4" unitRef="usd">1250000.0</pharmabioserv.com:PromissoryNoteReceivable>
  <us-gaap:OtherLiabilities id="f39" decimals="0" contextRef="c4" unitRef="usd">17950.0</us-gaap:OtherLiabilities>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="f40" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Owned property and equipment,&#13;and leasehold improvements are stated at cost. Vehicles under capital leases are stated at the lower of fair market value or net&#13;present value of the minimum lease payments at the inception of the leases.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Depreciation and amortization&#13;of owned assets are provided for, when placed in service, in amounts sufficient to relate the cost of depreciable assets to operations&#13;over their estimated service lives, using straight-line basis. Assets under capital leases and leasehold improvements are amortized&#13;over the shorter of the estimated useful lives of the assets or the lease term, including renewals that have been determined to&#13;be reasonable assured. Major renewals and betterments that extend the life of the assets are capitalized, while expenditures for&#13;repairs and maintenance are expensed when incurred. As of July 31, 2019 and October 31, 2018, the accumulated depreciation and&#13;amortization amounted to $483,983 and $496,953, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The Company evaluates for impairment&#13;its long-lived assets to be held and used, and long-lived assets to be disposed of, whenever events or changes in circumstances&#13;indicate that the carrying amount of an asset may not be recoverable. Based on management estimates, no impairment of the operating&#13;properties was present as of July 31, 2019 and October 31, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:CommonStockSharesOutstanding id="f41" decimals="INF" contextRef="c" unitRef="shares">22995881.0</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="f42" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 6.6pt 0pt; text-align: justify"&gt;In May 2014, the Financial&#13;Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for the recognition of revenue from&#13;contracts with customers to transfer goods and services. The FASB subsequently issued additional, clarifying standards to address&#13;issues arising from implementation of the new revenue recognition standard. The new revenue recognition standard and clarifying&#13;standards require an entity to recognize revenue when control of promised goods or services is transferred to the customer at an&#13;amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We adopted&#13;this new standard as of November 1, 2018, by applying the modified-retrospective method to those contracts that were not completed&#13;as of that date. The results for reporting periods beginning after November 1, 2018, are presented in accordance with the new standard,&#13;although comparative information has not been restated and continues to be reported under the accounting standards and policies&#13;in effect for those periods. The adoption of this new standard had an immaterial impact on our reported total revenues and operating&#13;income as compared to what reported amounts would have been under the prior standard.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Revenue is primarily derived&#13;from: (1) time and materials contracts (representing approximately 99% of total revenues), which is recognized by applying the&#13;proportional performance model, whereby revenue is recognized as performance occurs, and (2) short-term fixed-fee contracts or&#13;&amp;#34;not to exceed&amp;#34; contracts (representing approximately 1% of total revenues), which revenue is recognized similarly, except&#13;that certain milestones also have to be reached before revenue is recognized. If the Company determines that a contract will result&#13;in a loss, the Company recognizes the estimated loss in the period in which such determination is made.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:PreferredStockSharesOutstanding id="f43" decimals="INF" contextRef="c4" unitRef="shares">0.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ReceivablesPolicyTextBlock id="f44" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Accounts receivable are recorded&#13;at their estimated realizable value. Accounts are deemed past due when payment has not been received within the stated time period.&#13;The Company's policy is to review individual past due amounts periodically and write off amounts for which all collection efforts&#13;are deemed to have been exhausted. Due to the nature of the Company&amp;#8217;s customers, bad debts are mainly accounted for using&#13;the direct write-off method whereby an expense is recognized only when a specific account is determined to be uncollectible. The&#13;effect of using this method approximates that of the allowance method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
  <us-gaap:TreasuryStockShares id="f45" decimals="INF" contextRef="c" unitRef="shares">401826.0</us-gaap:TreasuryStockShares>
  <us-gaap:IncomeTaxPolicyTextBlock id="f46" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The Company follows an asset&#13;and liability approach method of accounting for income taxes. This method measures deferred income taxes by applying enacted statutory&#13;rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported&#13;amounts on the financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws&#13;as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The Company follows guidance&#13;from the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) related to &lt;i&gt;Accounting for Uncertainty in Income Taxes,&lt;/i&gt;&#13;which includes a two-step approach to recognizing, de-recognizing and measuring uncertain tax positions. As of July 31, 2019, the&#13;Company had no significant uncertain tax positions that would be reduced as a result of a lapse of the applicable statute of limitations.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:CommonStockSharesIssued id="f47" decimals="INF" contextRef="c4" unitRef="shares">23373817.0</us-gaap:CommonStockSharesIssued>
  <us-gaap:ShareBasedCompensation id="f48" decimals="0" contextRef="c5" unitRef="usd">17550.0</us-gaap:ShareBasedCompensation>
  <us-gaap:CommonStockSharesOutstanding id="f49" decimals="INF" contextRef="c4" unitRef="shares">23058413.0</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="f50" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Stock-based compensation expense&#13;is recognized in the consolidated financial statements based on the fair value of the awards granted. Stock-based compensation&#13;cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service&#13;period, which generally represents the vesting period, and includes an estimate of awards that will be forfeited. The Company calculates&#13;the fair value of stock options using the Black-Scholes option-pricing model at the grant date, while for restricted stock units&#13;the fair market value of the units is determined by Company&amp;#8217;s share market value at grant date. Excess tax benefits related&#13;to stock-based compensation are reflected as cash flows from financing activities rather than cash flows from operating activities.&#13;The Company has not recognized such cash flows from financing activities since there has been no tax benefit related to the stock-based&#13;compensation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:EarningsPerSharePolicyTextBlock id="f51" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Basic earnings (loss) per share&#13;of common stock is calculated by dividing net earnings (loss) by the weighted average number of shares of common stock outstanding.&#13;Diluted earnings (loss) per share includes the dilution of common stock equivalents, which include principally shares that may&#13;be issued upon the exercise of warrants, stock option and restricted stock unit awards.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The diluted weighted average&#13;shares of common stock outstanding were calculated using the treasury stock method for the respective periods.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="f52" decimals="0" contextRef="c" unitRef="usd">483983.0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock id="f53" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The functional currency of the&#13;Company&amp;#8217;s foreign subsidiaries is its local currency. The assets and liabilities of the Company&amp;#8217;s foreign subsidiaries&#13;are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated&#13;at the average exchange rates prevailing during the period. The cumulative translation effect for subsidiaries using a functional&#13;currency other than the U.S. dollar is included as a cumulative translation adjustment in stockholders&amp;#8217; equity and as a component&#13;of comprehensive income.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;The Company&amp;#8217;s intercompany&#13;accounts are typically denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement&#13;of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation&#13;adjustment in stockholders&amp;#8217; equity and as a component of comprehensive income, while gains and losses resulting from the&#13;remeasurement of intercompany receivables from those international subsidiaries for which the Company anticipates settlement in&#13;the foreseeable future are recorded in the consolidated statements of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:TreasuryStockShares id="f54" decimals="INF" contextRef="c4" unitRef="shares">315404.0</us-gaap:TreasuryStockShares>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription id="f55" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;Certain reclassifications have&#13;been made to the July 31, 2018 condensed consolidated financial statements to conform them to the July 31, 2019 condensed consolidated&#13;financial statements presentation. Such reclassifications do not affect net income (loss) as previously reported.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <us-gaap:ShareBasedCompensation id="f56" decimals="0" contextRef="c1" unitRef="usd">27000.0</us-gaap:ShareBasedCompensation>
  <pharmabioserv.com:EffectOfRestrictedStockUnitsToCommonStock id="f57" decimals="INF" contextRef="c1" unitRef="shares">0.0</pharmabioserv.com:EffectOfRestrictedStockUnitsToCommonStock>
  <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants id="f58" decimals="INF" contextRef="c5" unitRef="shares">0.0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="f59" decimals="0" contextRef="c4" unitRef="usd">496953.0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:ShareBasedCompensation id="f60" decimals="0" contextRef="c3" unitRef="usd">9000.0</us-gaap:ShareBasedCompensation>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="f61" contextRef="c1">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;In February 2016, the FASB issued&#13;a new accounting standard that amends the guidance for the accounting and disclosure of leases. This new standard requires that&#13;lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative&#13;information about their leasing arrangements. The new standard is effective for interim and annual periods beginning on January&#13;1, 2019 and may be adopted earlier. This standard is effective for the Company&amp;#8217;s first quarter of fiscal year 2020. The Company&#13;does not expect that this standard will have a material impact to its Consolidated Statements of Operations but expects that this&#13;standard will have a material impact on the assets and liabilities on its Consolidated Balance Sheets upon adoption.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants id="f62" decimals="INF" contextRef="c3" unitRef="shares">0.0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
  <us-gaap:ShareBasedCompensation id="f63" decimals="0" contextRef="c2" unitRef="usd">52650.0</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="f64" decimals="0" contextRef="c6" unitRef="usd">17550.0</us-gaap:ShareBasedCompensation>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="f65" contextRef="c1">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 3pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: white 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Three months ended July 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Nine months ended July 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 3pt solid; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCFFCC"&gt;&#13;    &lt;td style="vertical-align: bottom; width: 50%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;font style="font-size: 8pt"&gt;Net income (loss) available to common equity holders - used to compute basic and diluted earnings (losses) per share (continuing operations)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; border-bottom: Black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; border-bottom: Black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;431,158&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; border-bottom: Black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; border-bottom: Black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;721,819&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; border-bottom: Black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 8%; border-bottom: Black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,609,661&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; border-bottom: Black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1,759,178&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt"&gt;&lt;font style="font-size: 8pt"&gt;Net income (loss) available to common equity holders - used to compute basic and diluted earnings (losses) per share (discontinued operations)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,812&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(302,551&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCFFCC"&gt;&#13;    &lt;td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white"&gt;&#13;    &lt;td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt"&gt;&lt;font style="font-size: 8pt"&gt;Weighted average number of common shares - used to compute basic earnings (losses) per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;22,996,169&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,062,531 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,045,432&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,076,306&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCFFCC"&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;Effect of warrants to purchase common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;Effect of restricted stock units to common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCFFCC"&gt;&#13;    &lt;td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt"&gt;&lt;font style="font-size: 8pt"&gt;Effect of options to purchase common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;42,067&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12,075&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;63,320&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,452&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt"&gt;&lt;font style="font-size: 8pt"&gt;Weighted average number of shares - used to compute diluted earnings (losses) per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,038,236&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,074,606&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,108,752&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,080,758&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ShareBasedCompensation id="f66" decimals="0" contextRef="c7" unitRef="usd">17550.0</us-gaap:ShareBasedCompensation>
  <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants id="f67" decimals="INF" contextRef="c1" unitRef="shares">0.0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
  <us-gaap:ShareBasedCompensation id="f68" decimals="0" contextRef="c8" unitRef="usd">9000.0</us-gaap:ShareBasedCompensation>
  <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants id="f69" decimals="INF" contextRef="c2" unitRef="shares">0.0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
  <pharmabioserv.com:AntidilutiveWarrantsExcludedFromComputationOfEarningsPerShare id="f70" decimals="INF" contextRef="c1" unitRef="shares">1000000.0</pharmabioserv.com:AntidilutiveWarrantsExcludedFromComputationOfEarningsPerShare>
  <us-gaap:ShareBasedCompensation id="f71" decimals="0" contextRef="c9" unitRef="usd">9000.0</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="f72" decimals="0" contextRef="c10" unitRef="usd">17550.0</us-gaap:ShareBasedCompensation>
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements id="f73" decimals="INF" contextRef="c1" unitRef="shares">63320.0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <pharmabioserv.com:EffectOfRestrictedStockUnitsToCommonStock id="f74" decimals="INF" contextRef="c5" unitRef="shares">0.0</pharmabioserv.com:EffectOfRestrictedStockUnitsToCommonStock>
  <us-gaap:ShareBasedCompensation id="f75" decimals="0" contextRef="c11" unitRef="usd">9000.0</us-gaap:ShareBasedCompensation>
  <pharmabioserv.com:EffectOfRestrictedStockUnitsToCommonStock id="f76" decimals="INF" contextRef="c3" unitRef="shares">0.0</pharmabioserv.com:EffectOfRestrictedStockUnitsToCommonStock>
  <us-gaap:ShareBasedCompensation id="f77" decimals="0" contextRef="c12" unitRef="usd">9000.0</us-gaap:ShareBasedCompensation>
  <pharmabioserv.com:EffectOfRestrictedStockUnitsToCommonStock id="f78" decimals="INF" contextRef="c2" unitRef="shares">0.0</pharmabioserv.com:EffectOfRestrictedStockUnitsToCommonStock>
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements id="f79" decimals="INF" contextRef="c5" unitRef="shares">12075.0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <us-gaap:ShareBasedCompensation id="f80" decimals="0" contextRef="c13" unitRef="usd">17550.0</us-gaap:ShareBasedCompensation>
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements id="f81" decimals="INF" contextRef="c3" unitRef="shares">42067.0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <us-gaap:ShareBasedCompensation id="f82" decimals="0" contextRef="c14" unitRef="usd">9000.0</us-gaap:ShareBasedCompensation>
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements id="f83" decimals="INF" contextRef="c2" unitRef="shares">4452.0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <us-gaap:ConcentrationRiskPercentage1 id="f84" decimals="INF" contextRef="c15" unitRef="pure">0.131</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ShareBasedCompensation id="f85" decimals="0" contextRef="c16" unitRef="usd">17550.0</us-gaap:ShareBasedCompensation>
  <pharmabioserv.com:SharesPurchasedUnderRepurchaseProgramValue id="f86" decimals="0" contextRef="c" unitRef="usd">329607.0</pharmabioserv.com:SharesPurchasedUnderRepurchaseProgramValue>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f87" decimals="INF" contextRef="c1" unitRef="shares">80000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <pharmabioserv.com:AntidilutiveWarrantsExcludedFromComputationOfEarningsPerShare id="f88" decimals="INF" contextRef="c5" unitRef="shares">1000000.0</pharmabioserv.com:AntidilutiveWarrantsExcludedFromComputationOfEarningsPerShare>
  <pharmabioserv.com:SharesPurchasedUnderRepurchaseProgram id="f89" decimals="INF" contextRef="c" unitRef="shares">338854.0</pharmabioserv.com:SharesPurchasedUnderRepurchaseProgram>
  <us-gaap:SharesIssued id="f90" decimals="INF" contextRef="c17" unitRef="shares">0.0</us-gaap:SharesIssued>
  <pharmabioserv.com:AntidilutiveWarrantsExcludedFromComputationOfEarningsPerShare id="f91" decimals="INF" contextRef="c3" unitRef="shares">1000000.0</pharmabioserv.com:AntidilutiveWarrantsExcludedFromComputationOfEarningsPerShare>
  <pharmabioserv.com:AntidilutiveWarrantsExcludedFromComputationOfEarningsPerShare id="f92" decimals="INF" contextRef="c2" unitRef="shares">1000000.0</pharmabioserv.com:AntidilutiveWarrantsExcludedFromComputationOfEarningsPerShare>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f93" decimals="INF" contextRef="c5" unitRef="shares">620000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:SharesIssued id="f94" decimals="INF" contextRef="c18" unitRef="shares">23333083.0</us-gaap:SharesIssued>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f95" decimals="INF" contextRef="c3" unitRef="shares">240000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f96" decimals="INF" contextRef="c2" unitRef="shares">620000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <pharmabioserv.com:SharesPurchasedUnderRepurchaseProgram id="f97" decimals="INF" contextRef="c4" unitRef="shares">315404.0</pharmabioserv.com:SharesPurchasedUnderRepurchaseProgram>
  <us-gaap:ConcentrationRiskPercentage1 id="f98" decimals="INF" contextRef="c19" unitRef="pure">0.248</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="f99" decimals="INF" contextRef="c20" unitRef="pure">0.097</us-gaap:ConcentrationRiskPercentage1>
  <dei:EntityShellCompany id="f100" contextRef="c1">false</dei:EntityShellCompany>
  <pharmabioserv.com:SharesPurchasedUnderRepurchaseProgramValue id="f101" decimals="0" contextRef="c4" unitRef="usd">304688.0</pharmabioserv.com:SharesPurchasedUnderRepurchaseProgramValue>
  <us-gaap:ConcentrationRiskPercentage1 id="f102" decimals="INF" contextRef="c21" unitRef="pure">0.072</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:SharesIssued id="f103" decimals="INF" contextRef="c22" unitRef="shares">23333083.0</us-gaap:SharesIssued>
  <us-gaap:SharesIssued id="f104" decimals="INF" contextRef="c23" unitRef="shares">23373817.0</us-gaap:SharesIssued>
  <us-gaap:ConcentrationRiskPercentage1 id="f105" decimals="INF" contextRef="c24" unitRef="pure">0.031</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:SharesIssued id="f106" decimals="INF" contextRef="c25" unitRef="shares">0.0</us-gaap:SharesIssued>
  <us-gaap:SharesIssued id="f107" decimals="INF" contextRef="c26" unitRef="shares">23333083.0</us-gaap:SharesIssued>
  <us-gaap:ConcentrationRiskPercentage1 id="f108" decimals="INF" contextRef="c27" unitRef="pure">0.11</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:SharesIssued id="f109" decimals="INF" contextRef="c28" unitRef="shares">23377259.0</us-gaap:SharesIssued>
  <us-gaap:SharesIssued id="f110" decimals="INF" contextRef="c29" unitRef="shares">23397707.0</us-gaap:SharesIssued>
  <us-gaap:ConcentrationRiskPercentage1 id="f111" decimals="INF" contextRef="c30" unitRef="pure">0.141</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:SharesIssued id="f112" decimals="INF" contextRef="c31" unitRef="shares">0.0</us-gaap:SharesIssued>
  <us-gaap:SharesIssued id="f113" decimals="INF" contextRef="c32" unitRef="shares">0.0</us-gaap:SharesIssued>
  <us-gaap:ConcentrationRiskPercentage1 id="f114" decimals="INF" contextRef="c33" unitRef="pure">0.674</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:SharesIssued id="f115" decimals="INF" contextRef="c34" unitRef="shares">0.0</us-gaap:SharesIssued>
  <us-gaap:SharesIssued id="f116" decimals="INF" contextRef="c35" unitRef="shares">0.0</us-gaap:SharesIssued>
  <us-gaap:ConcentrationRiskPercentage1 id="f117" decimals="INF" contextRef="c36" unitRef="pure">0.544</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:SharesIssued id="f118" decimals="INF" contextRef="c37" unitRef="shares">23397707.0</us-gaap:SharesIssued>
  <us-gaap:SharesIssued id="f119" decimals="INF" contextRef="c38" unitRef="shares">23333083.0</us-gaap:SharesIssued>
  <us-gaap:ConcentrationRiskPercentage1 id="f120" decimals="INF" contextRef="c39" unitRef="pure">0.102</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:SharesIssued id="f121" decimals="INF" contextRef="c40" unitRef="shares">0.0</us-gaap:SharesIssued>
  <us-gaap:SharesIssued id="f122" decimals="INF" contextRef="c41" unitRef="shares">0.0</us-gaap:SharesIssued>
  <us-gaap:ConcentrationRiskPercentage1 id="f123" decimals="INF" contextRef="c42" unitRef="pure">0.077</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f124" decimals="0" contextRef="c" unitRef="usd">21790691.0</us-gaap:StockholdersEquity>
  <us-gaap:ConcentrationRiskPercentage1 id="f125" decimals="INF" contextRef="c43" unitRef="pure">0.066</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f126" decimals="0" contextRef="c44" unitRef="usd">20747286.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f127" decimals="0" contextRef="c4" unitRef="usd">20263663.0</us-gaap:StockholdersEquity>
  <us-gaap:Revenues id="f128" decimals="0" contextRef="c45" unitRef="usd">266610.0</us-gaap:Revenues>
  <pharmabioserv.com:AccumulatedDepreciationOnPropertyAndEquipmentDisposed id="f129" decimals="0" contextRef="c1" unitRef="usd">86773.0</pharmabioserv.com:AccumulatedDepreciationOnPropertyAndEquipmentDisposed>
  <us-gaap:NetIncomeLoss id="f130" decimals="0" contextRef="c10" unitRef="usd">-2664012.0</us-gaap:NetIncomeLoss>
  <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations id="f131" decimals="0" contextRef="c1" unitRef="usd">0.0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
  <dei:EntityRegistrantName id="f132" contextRef="c1">Pharma-Bio Serv, Inc.</dei:EntityRegistrantName>
  <us-gaap:Revenues id="f133" decimals="0" contextRef="c46" unitRef="usd">1042086.0</us-gaap:Revenues>
  <us-gaap:StockholdersEquity id="f134" decimals="0" contextRef="c47" unitRef="usd">18717926.0</us-gaap:StockholdersEquity>
  <us-gaap:NetIncomeLoss id="f135" decimals="0" contextRef="c11" unitRef="usd">471020.0</us-gaap:NetIncomeLoss>
  <us-gaap:NetCashProvidedByUsedInDiscontinuedOperations id="f136" decimals="0" contextRef="c5" unitRef="usd">559219.0</us-gaap:NetCashProvidedByUsedInDiscontinuedOperations>
  <us-gaap:Revenues id="f137" decimals="0" contextRef="c48" unitRef="usd">160735.0</us-gaap:Revenues>
  <us-gaap:ConcentrationRiskPercentage1 id="f138" decimals="INF" contextRef="c49" unitRef="pure">0.3</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f139" decimals="0" contextRef="c22" unitRef="usd">2333.0</us-gaap:StockholdersEquity>
  <us-gaap:NetIncomeLoss id="f140" decimals="0" contextRef="c50" unitRef="usd">707483.0</us-gaap:NetIncomeLoss>
  <dei:CurrentFiscalYearEndDate id="f141" contextRef="c1">--10-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:Revenues id="f142" decimals="0" contextRef="c51" unitRef="usd">31403.0</us-gaap:Revenues>
  <us-gaap:NetCashProvidedByUsedInDiscontinuedOperations id="f143" decimals="0" contextRef="c3" unitRef="usd">0.0</us-gaap:NetCashProvidedByUsedInDiscontinuedOperations>
  <us-gaap:NetIncomeLoss id="f144" decimals="0" contextRef="c52" unitRef="usd">-128348.0</us-gaap:NetIncomeLoss>
  <us-gaap:StockholdersEquity id="f145" decimals="0" contextRef="c25" unitRef="usd">0.0</us-gaap:StockholdersEquity>
  <us-gaap:Revenues id="f146" decimals="0" contextRef="c3" unitRef="usd">4966519.0</us-gaap:Revenues>
  <us-gaap:ConcentrationRiskPercentage1 id="f147" decimals="INF" contextRef="c53" unitRef="pure">0.069</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:NetIncomeLoss id="f148" decimals="0" contextRef="c14" unitRef="usd">707483.0</us-gaap:NetIncomeLoss>
  <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations id="f149" decimals="0" contextRef="c1" unitRef="usd">0.0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
  <dei:EntityCentralIndexKey id="f150" contextRef="c1">0001304161</dei:EntityCentralIndexKey>
  <us-gaap:Revenues id="f151" decimals="0" contextRef="c5" unitRef="usd">4631303.0</us-gaap:Revenues>
  <us-gaap:StockholdersEquity id="f152" decimals="0" contextRef="c54" unitRef="usd">1295314.0</us-gaap:StockholdersEquity>
  <us-gaap:NetIncomeLoss id="f153" decimals="0" contextRef="c16" unitRef="usd">-128348.0</us-gaap:NetIncomeLoss>
  <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations id="f154" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
  <us-gaap:Revenues id="f155" decimals="0" contextRef="c55" unitRef="usd">3825157.0</us-gaap:Revenues>
  <us-gaap:ConcentrationRiskPercentage1 id="f156" decimals="INF" contextRef="c56" unitRef="pure">0.141</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f157" decimals="0" contextRef="c1" unitRef="usd">-21742.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations id="f158" decimals="0" contextRef="c3" unitRef="usd">0.0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
  <us-gaap:StockholdersEquity id="f159" decimals="0" contextRef="c57" unitRef="usd">19560131.0</us-gaap:StockholdersEquity>
  <us-gaap:Revenues id="f160" decimals="0" contextRef="c58" unitRef="usd">4383121.0</us-gaap:Revenues>
  <dei:DocumentType id="f161" contextRef="c1">10-Q</dei:DocumentType>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f162" decimals="0" contextRef="c59" unitRef="usd">81275.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:Revenues id="f163" decimals="0" contextRef="c60" unitRef="usd">502998.0</us-gaap:Revenues>
  <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations id="f164" decimals="0" contextRef="c2" unitRef="usd">0.0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
  <us-gaap:ConcentrationRiskPercentage1 id="f165" decimals="INF" contextRef="c61" unitRef="pure">0.018</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f166" decimals="0" contextRef="c62" unitRef="usd">137671.0</us-gaap:StockholdersEquity>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f167" decimals="0" contextRef="c5" unitRef="usd">-51798.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:Revenues id="f168" decimals="0" contextRef="c63" unitRef="usd">684051.0</us-gaap:Revenues>
  <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations id="f169" decimals="0" contextRef="c1" unitRef="usd">0.0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
  <dei:DocumentPeriodEndDate id="f170" contextRef="c1">2019-07-31</dei:DocumentPeriodEndDate>
  <us-gaap:StockholdersEquity id="f171" decimals="0" contextRef="c64" unitRef="usd">-248163.0</us-gaap:StockholdersEquity>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f172" decimals="0" contextRef="c3" unitRef="usd">-6317.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:Revenues id="f173" decimals="0" contextRef="c65" unitRef="usd">33379.0</us-gaap:Revenues>
  <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations id="f174" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
  <us-gaap:ConcentrationRiskPercentage1 id="f175" decimals="INF" contextRef="c66" unitRef="pure">0.096</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:PreferredStockSharesAuthorized id="f176" decimals="INF" contextRef="c" unitRef="shares">10000000.0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:Revenues id="f177" decimals="0" contextRef="c67" unitRef="usd">111156.0</us-gaap:Revenues>
  <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations id="f178" decimals="0" contextRef="c3" unitRef="usd">0.0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
  <dei:AmendmentFlag id="f179" contextRef="c1">false</dei:AmendmentFlag>
  <us-gaap:StockholdersEquity id="f180" decimals="0" contextRef="c23" unitRef="usd">2337.0</us-gaap:StockholdersEquity>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f181" decimals="0" contextRef="c2" unitRef="usd">-6622.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f182" decimals="0" contextRef="c68" unitRef="usd">-51798.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:Revenues id="f183" decimals="0" contextRef="c69" unitRef="usd">47021.0</us-gaap:Revenues>
  <us-gaap:ConcentrationRiskPercentage1 id="f184" decimals="INF" contextRef="c70" unitRef="pure">0.075</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations id="f185" decimals="0" contextRef="c2" unitRef="usd">0.0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
  <dei:EntityFilerCategory id="f186" contextRef="c1">Non-accelerated Filer</dei:EntityFilerCategory>
  <us-gaap:StockholdersEquity id="f187" decimals="0" contextRef="c17" unitRef="usd">0.0</us-gaap:StockholdersEquity>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f188" decimals="0" contextRef="c71" unitRef="usd">7842.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:Revenues id="f189" decimals="0" contextRef="c72" unitRef="usd">10939.0</us-gaap:Revenues>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="f190" decimals="0" contextRef="c1" unitRef="usd">-8652.0</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f191" decimals="0" contextRef="c73" unitRef="usd">-6317.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="f192" decimals="0" contextRef="c1" unitRef="usd">0.0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:ConcentrationRiskPercentage1 id="f193" decimals="INF" contextRef="c74" unitRef="pure">0.098</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f194" decimals="0" contextRef="c75" unitRef="usd">1346956.0</us-gaap:StockholdersEquity>
  <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations id="f195" decimals="0" contextRef="c5" unitRef="usd">559219.0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
  <dei:EntityCurrentReportingStatus id="f196" contextRef="c1">Yes</dei:EntityCurrentReportingStatus>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f197" decimals="0" contextRef="c10" unitRef="usd">81275.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="f198" decimals="INF" contextRef="c1" unitRef="usd1">0.07</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations id="f199" decimals="0" contextRef="c3" unitRef="usd">0.0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
  <us-gaap:StockholdersEquity id="f200" decimals="0" contextRef="c76" unitRef="usd">19111111.0</us-gaap:StockholdersEquity>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f201" decimals="0" contextRef="c11" unitRef="usd">7842.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:ConcentrationRiskPercentage1 id="f202" decimals="INF" contextRef="c77" unitRef="pure">0.098</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="f203" decimals="0" contextRef="c5" unitRef="usd">8812.0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f204" decimals="0" contextRef="c78" unitRef="usd">-23267.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations id="f205" decimals="0" contextRef="c2" unitRef="usd">403567.0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
  <us-gaap:StockholdersEquity id="f206" decimals="0" contextRef="c79" unitRef="usd">107947.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="f207" decimals="0" contextRef="c3" unitRef="usd">0.0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f208" decimals="0" contextRef="c80" unitRef="usd">-36099.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="f209" decimals="0" contextRef="c1" unitRef="usd">-1234226.0</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:ConcentrationRiskPercentage1 id="f210" decimals="INF" contextRef="c81" unitRef="pure">0.022</us-gaap:ConcentrationRiskPercentage1>
  <dei:DocumentFiscalYearFocus id="f211" contextRef="c1">2019</dei:DocumentFiscalYearFocus>
  <us-gaap:StockholdersEquity id="f212" decimals="0" contextRef="c82" unitRef="usd">-304688.0</us-gaap:StockholdersEquity>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f213" decimals="0" contextRef="c14" unitRef="usd">-23267.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="f214" decimals="0" contextRef="c2" unitRef="usd">-302551.0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="f215" decimals="0" contextRef="c5" unitRef="usd">-39547.0</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f216" decimals="0" contextRef="c16" unitRef="usd">-36099.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare id="f217" decimals="INF" contextRef="c1" unitRef="usd1">0.0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="f218" decimals="0" contextRef="c3" unitRef="usd">2488.0</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:ConcentrationRiskPercentage1 id="f219" decimals="INF" contextRef="c83" unitRef="pure">0.226</us-gaap:ConcentrationRiskPercentage1>
  <dei:DocumentFiscalPeriodFocus id="f220" contextRef="c1">Q3</dei:DocumentFiscalPeriodFocus>
  <us-gaap:StockholdersEquity id="f221" decimals="0" contextRef="c18" unitRef="usd">2333.0</us-gaap:StockholdersEquity>
  <pharmabioserv.com:StockIssuedDuringPeriodSharesStockOptionsExercisedCashless id="f222" decimals="INF" contextRef="c84" unitRef="shares">3442.0</pharmabioserv.com:StockIssuedDuringPeriodSharesStockOptionsExercisedCashless>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="f223" decimals="INF" contextRef="c5" unitRef="usd1">0.031</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <dei:EntitySmallBusiness id="f224" contextRef="c1">true</dei:EntitySmallBusiness>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="f225" decimals="0" contextRef="c2" unitRef="usd">-56970.0</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:StockholdersEquity id="f226" decimals="0" contextRef="c26" unitRef="usd">2333.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="f227" decimals="INF" contextRef="c3" unitRef="usd1">0.019</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:ConcentrationRiskPercentage1 id="f228" decimals="INF" contextRef="c85" unitRef="pure">0.692</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f229" decimals="INF" contextRef="c" unitRef="usd1">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless id="f230" decimals="0" contextRef="c14" unitRef="usd">-1.0</pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="f231" decimals="0" contextRef="c1" unitRef="usd">-152912.0</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:StockholdersEquity id="f232" decimals="0" contextRef="c28" unitRef="usd">2338.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="f233" decimals="INF" contextRef="c2" unitRef="usd1">-0.076</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="f234" decimals="0" contextRef="c5" unitRef="usd">1642376.0</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f235" decimals="INF" contextRef="c4" unitRef="usd1">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:ConcentrationRiskPercentage1 id="f236" decimals="INF" contextRef="c86" unitRef="pure">0.587</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:OperatingIncomeLoss id="f237" decimals="0" contextRef="c1" unitRef="usd">1609661.0</us-gaap:OperatingIncomeLoss>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="f238" decimals="INF" contextRef="c1" unitRef="shares">23045432.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="f239" decimals="0" contextRef="c3" unitRef="usd">-637417.0</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:StockholdersEquity id="f240" decimals="0" contextRef="c29" unitRef="usd">2340.0</us-gaap:StockholdersEquity>
  <dei:EntityCommonStockSharesOutstanding id="f241" decimals="INF" contextRef="c87" unitRef="shares">22995881.0</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare id="f242" decimals="INF" contextRef="c5" unitRef="usd1">0.001</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="f243" decimals="0" contextRef="c2" unitRef="usd">3123424.0</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:ConcentrationRiskPercentage1 id="f244" decimals="INF" contextRef="c88" unitRef="pure">0.035</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CommonStockParOrStatedValuePerShare id="f245" decimals="INF" contextRef="c" unitRef="usd1">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:StockholdersEquity id="f246" decimals="0" contextRef="c31" unitRef="usd">0.0</us-gaap:StockholdersEquity>
  <pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless id="f247" decimals="0" contextRef="c84" unitRef="usd">1.0</pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare id="f248" decimals="INF" contextRef="c3" unitRef="usd1">0.0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations id="f249" decimals="0" contextRef="c1" unitRef="usd">65021.0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <pharmabioserv.com:StockIssuedDuringPeriodSharesStockOptionsExercisedCashless id="f250" decimals="INF" contextRef="c89" unitRef="shares">20448.0</pharmabioserv.com:StockIssuedDuringPeriodSharesStockOptionsExercisedCashless>
  <us-gaap:StockholdersEquity id="f251" decimals="0" contextRef="c32" unitRef="usd">0.0</us-gaap:StockholdersEquity>
  <pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless id="f252" decimals="0" contextRef="c50" unitRef="usd">-3.0</pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare id="f253" decimals="INF" contextRef="c2" unitRef="usd1">-0.013</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="f254" decimals="0" contextRef="c5" unitRef="usd">-3347.0</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ConcentrationRiskPercentage1 id="f255" decimals="INF" contextRef="c90" unitRef="pure">0.101</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:PreferredStockSharesAuthorized id="f256" decimals="INF" contextRef="c4" unitRef="shares">10000000.0</us-gaap:PreferredStockSharesAuthorized>
  <pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless id="f257" decimals="0" contextRef="c89" unitRef="usd">2.0</pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="f258" decimals="INF" contextRef="c1" unitRef="shares">23108752.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="f259" decimals="0" contextRef="c3" unitRef="usd">-3203.0</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:StockholdersEquity id="f260" decimals="0" contextRef="c34" unitRef="usd">0.0</us-gaap:StockholdersEquity>
  <pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless id="f261" decimals="0" contextRef="c11" unitRef="usd">1.0</pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="f262" decimals="INF" contextRef="c5" unitRef="shares">23062531.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:ConcentrationRiskPercentage1 id="f263" decimals="INF" contextRef="c91" unitRef="pure">0.051</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CommonStockSharesAuthorized id="f264" decimals="INF" contextRef="c" unitRef="shares">50000000.0</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="f265" decimals="0" contextRef="c2" unitRef="usd">-23619.0</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:StockholdersEquity id="f266" decimals="0" contextRef="c35" unitRef="usd">0.0</us-gaap:StockholdersEquity>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="f267" decimals="INF" contextRef="c3" unitRef="shares">22996169.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:OperatingIncomeLoss id="f268" decimals="0" contextRef="c3" unitRef="usd">431158.0</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="f269" decimals="0" contextRef="c1" unitRef="usd">595267.0</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:CommonStockParOrStatedValuePerShare id="f270" decimals="INF" contextRef="c4" unitRef="usd1">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:ConcentrationRiskPercentage1 id="f271" decimals="INF" contextRef="c92" unitRef="pure">0.092</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f272" decimals="0" contextRef="c93" unitRef="usd">1312864.0</us-gaap:StockholdersEquity>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="f273" decimals="INF" contextRef="c2" unitRef="shares">23076306.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations id="f274" decimals="0" contextRef="c5" unitRef="usd">3347.0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:OperatingIncomeLoss id="f275" decimals="0" contextRef="c5" unitRef="usd">721819.0</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent id="f276" decimals="0" contextRef="c1" unitRef="usd">-17267.0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations id="f277" decimals="0" contextRef="c3" unitRef="usd">2631.0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:StockholdersEquity id="f278" decimals="0" contextRef="c94" unitRef="usd">1347964.0</us-gaap:StockholdersEquity>
  <us-gaap:ConcentrationRiskPercentage1 id="f279" decimals="INF" contextRef="c95" unitRef="pure">0.3</us-gaap:ConcentrationRiskPercentage1>
  <dei:EntityEmergingGrowthCompany id="f280" contextRef="c1">false</dei:EntityEmergingGrowthCompany>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="f281" decimals="INF" contextRef="c5" unitRef="shares">23074606.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations id="f282" decimals="0" contextRef="c2" unitRef="usd">9960.0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:StockholdersEquity id="f283" decimals="0" contextRef="c96" unitRef="usd">1355956.0</us-gaap:StockholdersEquity>
  <us-gaap:OperatingIncomeLoss id="f284" decimals="0" contextRef="c2" unitRef="usd">-1759178.0</us-gaap:OperatingIncomeLoss>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="f285" decimals="INF" contextRef="c3" unitRef="shares">23038236.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="f286" decimals="0" contextRef="c1" unitRef="usd">87891.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="f287" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:ConcentrationRiskPercentage1 id="f288" decimals="INF" contextRef="c97" unitRef="pure">0.173</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CommonStockSharesAuthorized id="f289" decimals="INF" contextRef="c4" unitRef="shares">50000000.0</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:StockholdersEquity id="f290" decimals="0" contextRef="c98" unitRef="usd">1373956.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeTaxExpenseBenefit id="f291" decimals="0" contextRef="c1" unitRef="usd">129595.0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="f292" decimals="INF" contextRef="c2" unitRef="shares">23080758.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="f293" decimals="0" contextRef="c3" unitRef="usd">572.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="f294" decimals="0" contextRef="c1" unitRef="usd">0.0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:ConcentrationRiskPercentage1 id="f295" decimals="INF" contextRef="c99" unitRef="pure">0.098</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f296" decimals="0" contextRef="c100" unitRef="usd">16896119.0</us-gaap:StockholdersEquity>
  <us-gaap:CapitalLeaseObligationsCurrent id="f297" decimals="0" contextRef="c" unitRef="usd">10882.0</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:IncomeTaxExpenseBenefit id="f298" decimals="0" contextRef="c5" unitRef="usd">52966.0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent id="f299" decimals="0" contextRef="c5" unitRef="usd">-54292.0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:AccruedIncomeTaxesCurrent id="f300" decimals="0" contextRef="c" unitRef="usd">342266.0</us-gaap:AccruedIncomeTaxesCurrent>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="f301" decimals="0" contextRef="c2" unitRef="usd">13659.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:StockholdersEquity id="f302" decimals="0" contextRef="c101" unitRef="usd">17498402.0</us-gaap:StockholdersEquity>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent id="f303" decimals="0" contextRef="c3" unitRef="usd">-6317.0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:ConcentrationRiskPercentage1 id="f304" decimals="INF" contextRef="c102" unitRef="pure">0.096</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:IncomeTaxExpenseBenefit id="f305" decimals="0" contextRef="c3" unitRef="usd">11382.0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:StockholdersEquity id="f306" decimals="0" contextRef="c103" unitRef="usd">19582131.0</us-gaap:StockholdersEquity>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent id="f307" decimals="0" contextRef="c2" unitRef="usd">-18735.0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:ProceedsFromCollectionOfOtherReceivables id="f308" decimals="0" contextRef="c1" unitRef="usd">500000.0</us-gaap:ProceedsFromCollectionOfOtherReceivables>
  <us-gaap:ConcentrationRiskPercentage1 id="f309" decimals="INF" contextRef="c104" unitRef="pure">0.022</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:IncomeTaxExpenseBenefit id="f310" decimals="0" contextRef="c2" unitRef="usd">2753989.0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentOfNoncreditPortionIncludedInNetIncomeAvailabeforsaleSecuritiesBeforeTax id="f311" decimals="0" contextRef="c1" unitRef="usd">-4475.0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentOfNoncreditPortionIncludedInNetIncomeAvailabeforsaleSecuritiesBeforeTax>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="f312" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:StockholdersEquity id="f313" decimals="0" contextRef="c105" unitRef="usd">20720769.0</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesCurrent id="f314" decimals="0" contextRef="c" unitRef="usd">2102549.0</us-gaap:LiabilitiesCurrent>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f315" decimals="0" contextRef="c1" unitRef="usd">1739256.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="f316" decimals="0" contextRef="c5" unitRef="usd">2494.0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="f317" decimals="0" contextRef="c3" unitRef="usd">-9402.0</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ConcentrationRiskPercentage1 id="f318" decimals="INF" contextRef="c106" unitRef="pure">0.035</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f319" decimals="0" contextRef="c107" unitRef="usd">218946.0</us-gaap:StockholdersEquity>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="f320" decimals="0" contextRef="c3" unitRef="usd">0.0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="f321" decimals="0" contextRef="c" unitRef="usd">1749401.0</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f322" decimals="0" contextRef="c108" unitRef="usd">-35717.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="f323" decimals="0" contextRef="c2" unitRef="usd">-57764.0</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:StockholdersEquity id="f324" decimals="0" contextRef="c109" unitRef="usd">131049.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f325" decimals="0" contextRef="c110" unitRef="usd">520786.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="f326" decimals="0" contextRef="c2" unitRef="usd">12113.0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:ConcentrationRiskPercentage1 id="f327" decimals="INF" contextRef="c111" unitRef="pure">0.724</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:LiabilitiesCurrent id="f328" decimals="0" contextRef="c4" unitRef="usd">2565672.0</us-gaap:LiabilitiesCurrent>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f329" decimals="0" contextRef="c112" unitRef="usd">1315937.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:InterestPaidNet id="f330" decimals="0" contextRef="c1" unitRef="usd">3000.0</us-gaap:InterestPaidNet>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="f331" decimals="0" contextRef="c1" unitRef="usd">99038.0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:StockholdersEquity id="f332" decimals="0" contextRef="c113" unitRef="usd">115789.0</us-gaap:StockholdersEquity>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentOfNoncreditPortionIncludedInNetIncomeAvailabeforsaleSecuritiesBeforeTax id="f333" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentOfNoncreditPortionIncludedInNetIncomeAvailabeforsaleSecuritiesBeforeTax>
  <us-gaap:ProceedsFromCollectionOfOtherReceivables id="f334" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:ProceedsFromCollectionOfOtherReceivables>
  <us-gaap:ConcentrationRiskPercentage1 id="f335" decimals="INF" contextRef="c114" unitRef="pure">0.069</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:AccruedIncomeTaxesCurrent id="f336" decimals="0" contextRef="c4" unitRef="usd">411903.0</us-gaap:AccruedIncomeTaxesCurrent>
  <us-gaap:StockholdersEquity id="f337" decimals="0" contextRef="c115" unitRef="usd">86205.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f338" decimals="0" contextRef="c2" unitRef="usd">994811.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentOfNoncreditPortionIncludedInNetIncomeAvailabeforsaleSecuritiesBeforeTax id="f339" decimals="0" contextRef="c3" unitRef="usd">0.0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentOfNoncreditPortionIncludedInNetIncomeAvailabeforsaleSecuritiesBeforeTax>
  <us-gaap:ProceedsFromCollectionOfOtherReceivables id="f340" decimals="0" contextRef="c3" unitRef="usd">0.0</us-gaap:ProceedsFromCollectionOfOtherReceivables>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f341" decimals="0" contextRef="c116" unitRef="usd">-132964.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:ConcentrationRiskPercentage1 id="f342" decimals="INF" contextRef="c117" unitRef="pure">0.042</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f343" decimals="0" contextRef="c118" unitRef="usd">-261822.0</us-gaap:StockholdersEquity>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentOfNoncreditPortionIncludedInNetIncomeAvailabeforsaleSecuritiesBeforeTax id="f344" decimals="0" contextRef="c2" unitRef="usd">0.0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentOfNoncreditPortionIncludedInNetIncomeAvailabeforsaleSecuritiesBeforeTax>
  <us-gaap:ProceedsFromCollectionOfOtherReceivables id="f345" decimals="0" contextRef="c2" unitRef="usd">0.0</us-gaap:ProceedsFromCollectionOfOtherReceivables>
  <us-gaap:Liabilities id="f346" decimals="0" contextRef="c" unitRef="usd">4460391.0</us-gaap:Liabilities>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f347" decimals="0" contextRef="c45" unitRef="usd">-145893.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:ComprehensiveIncomeNetOfTax id="f348" decimals="0" contextRef="c1" unitRef="usd">1587919.0</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="f349" decimals="0" contextRef="c1" unitRef="usd">48246.0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:StockholdersEquity id="f350" decimals="0" contextRef="c119" unitRef="usd">-261822.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f351" decimals="0" contextRef="c46" unitRef="usd">72884.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:ConcentrationRiskPercentage1 id="f352" decimals="INF" contextRef="c120" unitRef="pure">0.098</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ComprehensiveIncomeNetOfTax id="f353" decimals="0" contextRef="c3" unitRef="usd">424841.0</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="f354" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f355" decimals="0" contextRef="c48" unitRef="usd">604929.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="f356" decimals="0" contextRef="c4" unitRef="usd">2140001.0</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:StockholdersEquity id="f357" decimals="0" contextRef="c121" unitRef="usd">-370443.0</us-gaap:StockholdersEquity>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="f358" decimals="0" contextRef="c3" unitRef="usd">0.0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:CapitalLeaseObligationsNoncurrent id="f359" decimals="0" contextRef="c" unitRef="usd">69892.0</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f360" decimals="0" contextRef="c51" unitRef="usd">534105.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:ConcentrationRiskPercentage1 id="f361" decimals="INF" contextRef="c122" unitRef="pure">0.075</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f362" decimals="0" contextRef="c123" unitRef="usd">-392579.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f363" decimals="0" contextRef="c3" unitRef="usd">442540.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f364" decimals="0" contextRef="c124" unitRef="usd">12916944.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ComprehensiveIncomeNetOfTax id="f365" decimals="0" contextRef="c2" unitRef="usd">-2068351.0</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="f366" decimals="0" contextRef="c2" unitRef="usd">0.0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f367" decimals="0" contextRef="c5" unitRef="usd">774785.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="f368" decimals="0" contextRef="c1" unitRef="usd">-1667929.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:ConcentrationRiskPercentage1 id="f369" decimals="INF" contextRef="c125" unitRef="pure">0.226</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f370" decimals="0" contextRef="c126" unitRef="usd">18168440.0</us-gaap:StockholdersEquity>
  <us-gaap:ComprehensiveIncomeNetOfTax id="f371" decimals="0" contextRef="c5" unitRef="usd">678833.0</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:CapitalLeaseObligationsCurrent id="f372" decimals="0" contextRef="c4" unitRef="usd">13768.0</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f373" decimals="0" contextRef="c55" unitRef="usd">535526.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="f374" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:TaxesPayableCurrent id="f375" decimals="0" contextRef="c" unitRef="usd">2270000.0</us-gaap:TaxesPayableCurrent>
  <us-gaap:StockholdersEquity id="f376" decimals="0" contextRef="c127" unitRef="usd">20685771.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f377" decimals="0" contextRef="c58" unitRef="usd">359648.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="f378" decimals="0" contextRef="c3" unitRef="usd">9402.0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ConcentrationRiskPercentage1 id="f379" decimals="INF" contextRef="c128" unitRef="pure">0.101</us-gaap:ConcentrationRiskPercentage1>
  <pharmabioserv.com:StockRepurchaseDuringPeriodShares id="f380" decimals="INF" contextRef="c3" unitRef="shares">600.0</pharmabioserv.com:StockRepurchaseDuringPeriodShares>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f381" decimals="0" contextRef="c60" unitRef="usd">-38037.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:StockholdersEquity id="f382" decimals="0" contextRef="c37" unitRef="usd">2340.0</us-gaap:StockholdersEquity>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="f383" decimals="0" contextRef="c2" unitRef="usd">57764.0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f384" decimals="0" contextRef="c63" unitRef="usd">42737.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <pharmabioserv.com:DisposalOfMarketableSecurities id="f385" decimals="0" contextRef="c1" unitRef="usd">-44475.0</pharmabioserv.com:DisposalOfMarketableSecurities>
  <us-gaap:ConcentrationRiskPercentage1 id="f386" decimals="INF" contextRef="c129" unitRef="pure">0.611</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:Liabilities id="f387" decimals="0" contextRef="c4" unitRef="usd">5114649.0</us-gaap:Liabilities>
  <us-gaap:StockholdersEquity id="f388" decimals="0" contextRef="c38" unitRef="usd">2333.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f389" decimals="0" contextRef="c65" unitRef="usd">-87968.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <pharmabioserv.com:StockRepurchaseDuringPeriodShares id="f390" decimals="INF" contextRef="c11" unitRef="shares">65772.0</pharmabioserv.com:StockRepurchaseDuringPeriodShares>
  <pharmabioserv.com:DisposalOfMarketableSecurities id="f391" decimals="0" contextRef="c5" unitRef="usd">0.0</pharmabioserv.com:DisposalOfMarketableSecurities>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="f392" decimals="0" contextRef="c" unitRef="usd">20720769.0</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquityBeforeTreasuryStock id="f393" decimals="0" contextRef="c" unitRef="usd">22183270.0</us-gaap:StockholdersEquityBeforeTreasuryStock>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f394" decimals="0" contextRef="c67" unitRef="usd">-104921.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:ConcentrationRiskPercentage1 id="f395" decimals="INF" contextRef="c130" unitRef="pure">0.248</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f396" decimals="0" contextRef="c40" unitRef="usd">0.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f397" decimals="0" contextRef="c69" unitRef="usd">208897.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <pharmabioserv.com:StockRepurchaseDuringPeriodShares id="f398" decimals="INF" contextRef="c10" unitRef="shares">27100.0</pharmabioserv.com:StockRepurchaseDuringPeriodShares>
  <pharmabioserv.com:DisposalOfMarketableSecurities id="f399" decimals="0" contextRef="c3" unitRef="usd">0.0</pharmabioserv.com:DisposalOfMarketableSecurities>
  <us-gaap:CapitalLeaseObligationsNoncurrent id="f400" decimals="0" contextRef="c4" unitRef="usd">46027.0</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:StockholdersEquity id="f401" decimals="0" contextRef="c41" unitRef="usd">0.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f402" decimals="0" contextRef="c72" unitRef="usd">301443.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:ConcentrationRiskPercentage1 id="f403" decimals="INF" contextRef="c131" unitRef="pure">0.129</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:PreferredStockValue id="f404" decimals="0" contextRef="c" unitRef="usd">0.0</us-gaap:PreferredStockValue>
  <us-gaap:GrossProfit id="f405" decimals="0" contextRef="c1" unitRef="usd">4638386.0</us-gaap:GrossProfit>
  <pharmabioserv.com:StockRepurchaseDuringPeriodShares id="f406" decimals="INF" contextRef="c14" unitRef="shares">20050.0</pharmabioserv.com:StockRepurchaseDuringPeriodShares>
  <us-gaap:StockholdersEquity id="f407" decimals="0" contextRef="c132" unitRef="usd">1364956.0</us-gaap:StockholdersEquity>
  <pharmabioserv.com:DisposalOfMarketableSecurities id="f408" decimals="0" contextRef="c2" unitRef="usd">0.0</pharmabioserv.com:DisposalOfMarketableSecurities>
  <us-gaap:NonoperatingIncomeExpense id="f409" decimals="0" contextRef="c1" unitRef="usd">469131.0</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ConcentrationRiskPercentage1 id="f410" decimals="INF" contextRef="c133" unitRef="pure">0.11</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:TaxesPayableCurrent id="f411" decimals="0" contextRef="c4" unitRef="usd">2485000.0</us-gaap:TaxesPayableCurrent>
  <us-gaap:StockholdersEquity id="f412" decimals="0" contextRef="c134" unitRef="usd">1330414.0</us-gaap:StockholdersEquity>
  <us-gaap:NonoperatingIncomeExpense id="f413" decimals="0" contextRef="c3" unitRef="usd">81844.0</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:InterestPaidNet id="f414" decimals="0" contextRef="c5" unitRef="usd">519.0</us-gaap:InterestPaidNet>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="f415" decimals="0" contextRef="c5" unitRef="usd">1685270.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:ConcentrationRiskPercentage1 id="f416" decimals="INF" contextRef="c135" unitRef="pure">0.102</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="f417" decimals="0" contextRef="c" unitRef="usd">86205.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:StockholdersEquity id="f418" decimals="0" contextRef="c136" unitRef="usd">20289611.0</us-gaap:StockholdersEquity>
  <us-gaap:InterestPaidNet id="f419" decimals="0" contextRef="c3" unitRef="usd">1096.0</us-gaap:InterestPaidNet>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="f420" decimals="0" contextRef="c3" unitRef="usd">-627300.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:StockholdersEquity id="f421" decimals="0" contextRef="c137" unitRef="usd">16767771.0</us-gaap:StockholdersEquity>
  <us-gaap:NonoperatingIncomeExpense id="f422" decimals="0" contextRef="c2" unitRef="usd">389521.0</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ConcentrationRiskPercentage1 id="f423" decimals="INF" contextRef="c138" unitRef="pure">0.066</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:PreferredStockValue id="f424" decimals="0" contextRef="c4" unitRef="usd">0.0</us-gaap:PreferredStockValue>
  <us-gaap:InterestPaidNet id="f425" decimals="0" contextRef="c2" unitRef="usd">1610.0</us-gaap:InterestPaidNet>
  <us-gaap:LiabilitiesAndStockholdersEquity id="f426" decimals="0" contextRef="c" unitRef="usd">26251082.0</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:StockholdersEquity id="f427" decimals="0" contextRef="c139" unitRef="usd">92522.0</us-gaap:StockholdersEquity>
  <us-gaap:NonoperatingIncomeExpense id="f428" decimals="0" contextRef="c5" unitRef="usd">351071.0</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeTaxesPaid id="f429" decimals="0" contextRef="c1" unitRef="usd">326898.0</us-gaap:IncomeTaxesPaid>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="f430" decimals="0" contextRef="c2" unitRef="usd">3261777.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments id="f431" decimals="0" contextRef="c1" unitRef="usd">-4475.0</us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments>
  <us-gaap:ConcentrationRiskPercentage1 id="f432" decimals="INF" contextRef="c140" unitRef="pure">0.051</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquityBeforeTreasuryStock id="f433" decimals="0" contextRef="c4" unitRef="usd">20568351.0</us-gaap:StockholdersEquityBeforeTreasuryStock>
  <us-gaap:StockholdersEquity id="f434" decimals="0" contextRef="c141" unitRef="usd">182847.0</us-gaap:StockholdersEquity>
  <pharmabioserv.com:ObligationsUnderCapitalLeaseIncurredForAcquisitionOfVehicle id="f435" decimals="0" contextRef="c1" unitRef="usd">86000.0</pharmabioserv.com:ObligationsUnderCapitalLeaseIncurredForAcquisitionOfVehicle>
  <us-gaap:IncreaseDecreaseInOperatingLiabilities id="f436" decimals="0" contextRef="c1" unitRef="usd">-674324.0</us-gaap:IncreaseDecreaseInOperatingLiabilities>
  <us-gaap:IncomeLossFromContinuingOperations id="f437" decimals="0" contextRef="c1" unitRef="usd">1270125.0</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncreaseDecreaseInOperatingLiabilities id="f438" decimals="0" contextRef="c5" unitRef="usd">104015.0</us-gaap:IncreaseDecreaseInOperatingLiabilities>
  <us-gaap:IncomeTaxesPaid id="f439" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:IncomeTaxesPaid>
  <us-gaap:ConcentrationRiskPercentage1 id="f440" decimals="INF" contextRef="c142" unitRef="pure">0.706</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f441" decimals="0" contextRef="c143" unitRef="usd">-392007.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperations id="f442" decimals="0" contextRef="c3" unitRef="usd">360696.0</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncomeTaxesPaid id="f443" decimals="0" contextRef="c3" unitRef="usd">0.0</us-gaap:IncomeTaxesPaid>
  <us-gaap:IncreaseDecreaseInOperatingLiabilities id="f444" decimals="0" contextRef="c3" unitRef="usd">166107.0</us-gaap:IncreaseDecreaseInOperatingLiabilities>
  <us-gaap:CommonStockValue id="f445" decimals="0" contextRef="c" unitRef="usd">2340.0</us-gaap:CommonStockValue>
  <us-gaap:StockholdersEquity id="f446" decimals="0" contextRef="c144" unitRef="usd">-261822.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperations id="f447" decimals="0" contextRef="c2" unitRef="usd">605290.0</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:ConcentrationRiskPercentage1 id="f448" decimals="INF" contextRef="c145" unitRef="pure">0.072</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:IncomeTaxesPaid id="f449" decimals="0" contextRef="c2" unitRef="usd">0.0</us-gaap:IncomeTaxesPaid>
  <us-gaap:PropertyPlantAndEquipmentDisposals id="f450" decimals="0" contextRef="c1" unitRef="usd">138419.0</us-gaap:PropertyPlantAndEquipmentDisposals>
  <us-gaap:IncreaseDecreaseInOperatingLiabilities id="f451" decimals="0" contextRef="c2" unitRef="usd">2927969.0</us-gaap:IncreaseDecreaseInOperatingLiabilities>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="f452" decimals="0" contextRef="c4" unitRef="usd">107947.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:StockholdersEquity id="f453" decimals="0" contextRef="c146" unitRef="usd">21357422.0</us-gaap:StockholdersEquity>
  <us-gaap:PropertyPlantAndEquipmentDisposals id="f454" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:PropertyPlantAndEquipmentDisposals>
  <us-gaap:ConcentrationRiskPercentage1 id="f455" decimals="INF" contextRef="c147" unitRef="pure">0.057</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="f456" decimals="0" contextRef="c" unitRef="usd">1373956.0</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:StockholdersEquity id="f457" decimals="0" contextRef="c124" unitRef="usd">18021543.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperations id="f458" decimals="0" contextRef="c5" unitRef="usd">423714.0</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:PropertyPlantAndEquipmentDisposals id="f459" decimals="0" contextRef="c3" unitRef="usd">0.0</us-gaap:PropertyPlantAndEquipmentDisposals>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="f460" decimals="0" contextRef="c1" unitRef="usd">41365.0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:ConcentrationRiskPercentage1 id="f461" decimals="INF" contextRef="c148" unitRef="pure">0.14</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="f462" decimals="0" contextRef="c4" unitRef="usd">19111111.0</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:NetIncomeLoss id="f463" decimals="0" contextRef="c1" unitRef="usd">1609661.0</us-gaap:NetIncomeLoss>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="f464" decimals="0" contextRef="c1" unitRef="usd">3368261.0</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="f465" decimals="0" contextRef="c3" unitRef="usd">121694.0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:PropertyPlantAndEquipmentDisposals id="f466" decimals="0" contextRef="c2" unitRef="usd">0.0</us-gaap:PropertyPlantAndEquipmentDisposals>
  <us-gaap:StockRepurchasedDuringPeriodValue id="f467" decimals="0" contextRef="c3" unitRef="usd">572.0</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="f468" decimals="0" contextRef="c3" unitRef="usd">1205228.0</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="f469" decimals="0" contextRef="c2" unitRef="usd">-27467.0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:ConcentrationRiskPercentage1 id="f470" decimals="INF" contextRef="c149" unitRef="pure">0.077</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="f471" decimals="0" contextRef="c4" unitRef="usd">1346956.0</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:NetCashProvidedByUsedInDiscontinuedOperations id="f472" decimals="0" contextRef="c1" unitRef="usd">0.0</us-gaap:NetCashProvidedByUsedInDiscontinuedOperations>
  <us-gaap:StockRepurchasedDuringPeriodValue id="f473" decimals="0" contextRef="c150" unitRef="usd">65755.0</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="f474" decimals="0" contextRef="c2" unitRef="usd">3207096.0</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="f475" decimals="0" contextRef="c5" unitRef="usd">140267.0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:ConcentrationRiskPercentage1 id="f476" decimals="INF" contextRef="c151" unitRef="pure">0.131</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:TreasuryStockValue id="f477" decimals="0" contextRef="c" unitRef="usd">392579.0</us-gaap:TreasuryStockValue>
  <us-gaap:StockRepurchasedDuringPeriodValue id="f478" decimals="0" contextRef="c152" unitRef="usd">13659.0</us-gaap:StockRepurchasedDuringPeriodValue>
  <pharmabioserv.com:ConversionOfCashlessExerciseOfOptionsToSharesOfCommonStock id="f479" decimals="0" contextRef="c1" unitRef="usd">3.0</pharmabioserv.com:ConversionOfCashlessExerciseOfOptionsToSharesOfCommonStock>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="f480" decimals="0" contextRef="c5" unitRef="usd">1170134.0</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="f481" decimals="0" contextRef="c1" unitRef="usd">2610837.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <pharmabioserv.com:ObligationsUnderCapitalLeaseIncurredForAcquisitionOfVehicle id="f482" decimals="0" contextRef="c5" unitRef="usd">0.0</pharmabioserv.com:ObligationsUnderCapitalLeaseIncurredForAcquisitionOfVehicle>
  <us-gaap:ConcentrationRiskPercentage1 id="f483" decimals="INF" contextRef="c153" unitRef="pure">0.093</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CommonStockValue id="f484" decimals="0" contextRef="c4" unitRef="usd">2337.0</us-gaap:CommonStockValue>
  <us-gaap:StockRepurchasedDuringPeriodValue id="f485" decimals="0" contextRef="c154" unitRef="usd">572.0</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:CostOfRevenue id="f486" decimals="0" contextRef="c1" unitRef="usd">10044674.0</us-gaap:CostOfRevenue>
  <pharmabioserv.com:ObligationsUnderCapitalLeaseIncurredForAcquisitionOfVehicle id="f487" decimals="0" contextRef="c3" unitRef="usd">0.0</pharmabioserv.com:ObligationsUnderCapitalLeaseIncurredForAcquisitionOfVehicle>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="f488" decimals="0" contextRef="c3" unitRef="usd">1136992.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f489" decimals="0" contextRef="c" unitRef="usd">14795694.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:GrossProfit id="f490" decimals="0" contextRef="c5" unitRef="usd">1593848.0</us-gaap:GrossProfit>
  <us-gaap:ConcentrationRiskPercentage1 id="f491" decimals="INF" contextRef="c155" unitRef="pure">0.57</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockRepurchasedDuringPeriodValue id="f492" decimals="0" contextRef="c10" unitRef="usd">13659.0</us-gaap:StockRepurchasedDuringPeriodValue>
  <pharmabioserv.com:ObligationsUnderCapitalLeaseIncurredForAcquisitionOfVehicle id="f493" decimals="0" contextRef="c2" unitRef="usd">0.0</pharmabioserv.com:ObligationsUnderCapitalLeaseIncurredForAcquisitionOfVehicle>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="f494" decimals="0" contextRef="c2" unitRef="usd">-1948132.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:GrossProfit id="f495" decimals="0" contextRef="c3" unitRef="usd">1565924.0</us-gaap:GrossProfit>
  <us-gaap:LiabilitiesAndStockholdersEquity id="f496" decimals="0" contextRef="c4" unitRef="usd">25378312.0</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:StockRepurchasedDuringPeriodValue id="f497" decimals="0" contextRef="c11" unitRef="usd">65755.0</us-gaap:StockRepurchasedDuringPeriodValue>
  <pharmabioserv.com:IncomeTaxWithheldByClientsToBeUsedAsCreditInCompanysIncomeTaxReturn id="f498" decimals="0" contextRef="c1" unitRef="usd">26526.0</pharmabioserv.com:IncomeTaxWithheldByClientsToBeUsedAsCreditInCompanysIncomeTaxReturn>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="f499" decimals="0" contextRef="c5" unitRef="usd">-961673.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock id="f500" contextRef="c1">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 3pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: white 3pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Three months ended July 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Nine months ended July 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 3pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 3pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: white 3pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-top: white 1pt solid; border-bottom: white 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: white 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;REVENUES:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; text-indent: 9pt"&gt;&lt;font style="font-size: 8pt"&gt;Puerto Rico consulting&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,383,121&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,825,157&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12,564,716&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;9,737,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-indent: 9pt"&gt;&lt;font style="font-size: 8pt"&gt;United States consulting&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;502,998&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;684,051&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,690,999&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,311,882&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-indent: 9pt"&gt;&lt;font style="font-size: 8pt"&gt;Europe consulting&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;33,379&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;111,156&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;266,610&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,042,086&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; padding-left: 0.25in; text-indent: -9pt"&gt;&lt;font style="font-size: 8pt"&gt;Other segments&amp;#185;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;47,021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10,939&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;160,735&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;31,403&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; padding-left: 0.25in; text-indent: -0.1pt"&gt;&lt;font style="font-size: 8pt"&gt;Total consolidated revenues&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: white"&gt;&lt;font style="font-size: 8pt"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,966,519&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: white"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,631,303&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: white"&gt;&lt;font style="font-size: 8pt"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;14,683,060&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: white"&gt;&lt;font style="font-size: 8pt"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12,123,257&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;INCOME (LOSS) BEFORE TAXES:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-indent: 9pt"&gt;&lt;font style="font-size: 8pt"&gt;Puerto Rico consulting&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;359,648&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;535,526&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,315,937&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;520,786&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-indent: 9pt"&gt;&lt;font style="font-size: 8pt"&gt;United States consulting&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(38,037&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;42,737&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(35,717&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(132,964&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: white"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-indent: 9pt"&gt;&lt;font style="font-size: 8pt"&gt;Europe consulting&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(87,968&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(104,921&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(145,893&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;72,884&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; text-indent: 9pt"&gt;&lt;font style="font-size: 8pt"&gt;Other segments&amp;#185;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;208,897&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;301,443&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom"&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;604,929&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;534,105&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC; text-indent: 17.9pt"&gt;&lt;font style="font-size: 8pt"&gt;Total consolidated income before taxes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;442,540&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;774,785&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,739,256&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: #CCFFCC"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 2.25pt double; background-color: #CCFFCC; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;994,811&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; background-color: #CCFFCC"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 4%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#185;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 59%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Other segments represent activities that fall below the reportable threshold and are carried out&#13;in Puerto Rico and Brazil. These activities include a Brazilian compliance consulting division and corporate headquarters, as&#13;applicable.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 37%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
  <us-gaap:GrossProfit id="f501" decimals="0" contextRef="c2" unitRef="usd">3812386.0</us-gaap:GrossProfit>
  <us-gaap:StockRepurchasedDuringPeriodValue id="f502" decimals="0" contextRef="c156" unitRef="usd">21564.0</us-gaap:StockRepurchasedDuringPeriodValue>
  <pharmabioserv.com:ConversionOfCashlessExerciseOfOptionsToSharesOfCommonStock id="f503" decimals="0" contextRef="c5" unitRef="usd">0.0</pharmabioserv.com:ConversionOfCashlessExerciseOfOptionsToSharesOfCommonStock>
  <us-gaap:AssetsCurrent id="f504" decimals="0" contextRef="c" unitRef="usd">24326718.0</us-gaap:AssetsCurrent>
  <us-gaap:GainLossOnDispositionOfAssets id="f505" decimals="0" contextRef="c1" unitRef="usd">47392.0</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:Revenues id="f506" decimals="0" contextRef="c1" unitRef="usd">14683060.0</us-gaap:Revenues>
  <pharmabioserv.com:ConversionOfCashlessExerciseOfOptionsToSharesOfCommonStock id="f507" decimals="0" contextRef="c3" unitRef="usd">0.0</pharmabioserv.com:ConversionOfCashlessExerciseOfOptionsToSharesOfCommonStock>
  <us-gaap:StockRepurchasedDuringPeriodValue id="f508" decimals="0" contextRef="c14" unitRef="usd">21564.0</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments id="f509" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments>
  <us-gaap:CostOfRevenue id="f510" decimals="0" contextRef="c5" unitRef="usd">3037455.0</us-gaap:CostOfRevenue>
  <pharmabioserv.com:ConversionOfCashlessExerciseOfOptionsToSharesOfCommonStock id="f511" decimals="0" contextRef="c2" unitRef="usd">0.0</pharmabioserv.com:ConversionOfCashlessExerciseOfOptionsToSharesOfCommonStock>
  <us-gaap:TreasuryStockValue id="f512" decimals="0" contextRef="c4" unitRef="usd">304688.0</us-gaap:TreasuryStockValue>
  <us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments id="f513" decimals="0" contextRef="c3" unitRef="usd">0.0</us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments>
  <us-gaap:NetIncomeLoss id="f514" decimals="0" contextRef="c157" unitRef="usd">-2664012.0</us-gaap:NetIncomeLoss>
  <us-gaap:CostOfRevenue id="f515" decimals="0" contextRef="c3" unitRef="usd">3400595.0</us-gaap:CostOfRevenue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f516" decimals="0" contextRef="c44" unitRef="usd">11591548.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="f517" decimals="0" contextRef="c1" unitRef="usd">-1234226.0</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:NetIncomeLoss id="f518" decimals="0" contextRef="c5" unitRef="usd">730631.0</us-gaap:NetIncomeLoss>
  <pharmabioserv.com:AmountDueFromMajorCustomersAsPercentageOfAccountsReceivable id="f519" decimals="INF" contextRef="c33" unitRef="pure">0.815</pharmabioserv.com:AmountDueFromMajorCustomersAsPercentageOfAccountsReceivable>
  <us-gaap:CostOfRevenue id="f520" decimals="0" contextRef="c2" unitRef="usd">8310871.0</us-gaap:CostOfRevenue>
  <pharmabioserv.com:IncomeTaxWithheldByClientsToBeUsedAsCreditInCompanysIncomeTaxReturn id="f521" decimals="0" contextRef="c5" unitRef="usd">1396.0</pharmabioserv.com:IncomeTaxWithheldByClientsToBeUsedAsCreditInCompanysIncomeTaxReturn>
  <us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments id="f522" decimals="0" contextRef="c2" unitRef="usd">0.0</us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments>
  <pharmabioserv.com:AmountDueFromMajorCustomersAsPercentageOfAccountsReceivable id="f523" decimals="INF" contextRef="c142" unitRef="pure">0.828</pharmabioserv.com:AmountDueFromMajorCustomersAsPercentageOfAccountsReceivable>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f524" decimals="0" contextRef="c4" unitRef="usd">16029920.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:NetIncomeLoss id="f525" decimals="0" contextRef="c3" unitRef="usd">431158.0</us-gaap:NetIncomeLoss>
  <us-gaap:Revenues id="f526" decimals="0" contextRef="c108" unitRef="usd">1690999.0</us-gaap:Revenues>
  <pharmabioserv.com:IncomeTaxWithheldByClientsToBeUsedAsCreditInCompanysIncomeTaxReturn id="f527" decimals="0" contextRef="c3" unitRef="usd">2526.0</pharmabioserv.com:IncomeTaxWithheldByClientsToBeUsedAsCreditInCompanysIncomeTaxReturn>
  <us-gaap:DepreciationDepletionAndAmortization id="f528" decimals="0" contextRef="c1" unitRef="usd">73803.0</us-gaap:DepreciationDepletionAndAmortization>
  <pharmabioserv.com:AmountDueFromMajorCustomersAsPercentageOfAccountsReceivable id="f529" decimals="INF" contextRef="c111" unitRef="pure">0.828</pharmabioserv.com:AmountDueFromMajorCustomersAsPercentageOfAccountsReceivable>
  <us-gaap:DepreciationDepletionAndAmortization id="f530" decimals="0" contextRef="c5" unitRef="usd">20480.0</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:Revenues id="f531" decimals="0" contextRef="c110" unitRef="usd">9737886.0</us-gaap:Revenues>
  <pharmabioserv.com:IncomeTaxWithheldByClientsToBeUsedAsCreditInCompanysIncomeTaxReturn id="f532" decimals="0" contextRef="c2" unitRef="usd">19641.0</pharmabioserv.com:IncomeTaxWithheldByClientsToBeUsedAsCreditInCompanysIncomeTaxReturn>
  <pharmabioserv.com:AmountDueFromMajorCustomersAsPercentageOfAccountsReceivable id="f533" decimals="INF" contextRef="c85" unitRef="pure">0.815</pharmabioserv.com:AmountDueFromMajorCustomersAsPercentageOfAccountsReceivable>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f534" decimals="0" contextRef="c47" unitRef="usd">15118539.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:NetIncomeLoss id="f535" decimals="0" contextRef="c2" unitRef="usd">-2061729.0</us-gaap:NetIncomeLoss>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="f536" decimals="0" contextRef="c5" unitRef="usd">2201595.0</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:Revenues id="f537" decimals="0" contextRef="c112" unitRef="usd">12564716.0</us-gaap:Revenues>
  <us-gaap:DepreciationDepletionAndAmortization id="f538" decimals="0" contextRef="c3" unitRef="usd">25121.0</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:NetIncomeLoss id="f539" decimals="0" contextRef="c158" unitRef="usd">730631.0</us-gaap:NetIncomeLoss>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="f540" decimals="0" contextRef="c3" unitRef="usd">-637417.0</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f541" decimals="0" contextRef="c146" unitRef="usd">15433111.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:NetIncomeLoss id="f542" decimals="0" contextRef="c159" unitRef="usd">471020.0</us-gaap:NetIncomeLoss>
  <us-gaap:Revenues id="f543" decimals="0" contextRef="c2" unitRef="usd">12123257.0</us-gaap:Revenues>
  <us-gaap:Revenues id="f544" decimals="0" contextRef="c116" unitRef="usd">1311882.0</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss id="f545" decimals="0" contextRef="c160" unitRef="usd">431158.0</us-gaap:NetIncomeLoss>
</xbrli:xbrl>
